KR20200011388A - Novel imidazole derivatives having jnk-inhibitory activity and pharmaceutical composition having the same - Google Patents

Abstract

In a novel imidazole derivative having JNK inhibitory activity of the present invention, pharmaceutically acceptable salt thereof, an optical isomer thereof, a hydrate or a solvate thereof, and a pharmaceutical composition comprising the same of the present invention, the imidazole derivative has a structure represented by chemical formula 1. The pharmaceutical composition can be usefully used for preventing and treating degenerative brain-nervous system diseases.

Description

Novel imidazole derivatives having JNK inhibitory activity and pharmaceutical compositions comprising same {NOVEL IMIDAZOLE DERIVATIVES HAVING JNK-INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION HAVING THE SAME}

The present invention relates to a novel imidazole derivative having a JNK (C-Jun N-terminal kinase) inhibitory activity, a pharmaceutically acceptable salt thereof, an optical isomer thereof, a hydrate or solvate thereof, and a pharmaceutical composition comprising the same. .

Recently, the number of patients suffering from degenerative cranial nervous system diseases is increasing rapidly in parallel with the increase of the elderly population. Degenerative cerebral nervous system diseases can be caused by secondary symptoms caused by adult diseases such as structural degeneration of cerebral nerve cells due to aging, circulatory disorders, or physical and mechanical factors such as traffic accidents, industrial accidents, carbon monoxide poisoning, and related diseases. Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and stroke are known.

Meanwhile, the c-Jun N-terminal kinase (JNK), which is classified as a serine / threonine kinase, is one of three subdependencies of mitogen-activated protein kinase, and is also referred to as stress activated protein kinase (SAPK). JNK is activated in response to a variety of stimuli such as cytokines, mitogens, osmotic stresses, and ultraviolet irradiations. These activated JNKs have numerous transcription factors including c-Jun of AP-1. It is known to promote phosphorylation of intracellular proteins such as Bcl2 and p53 related to cell death. In addition, JNK gene forms different heterologous proteins by splicing process. Among them, JNK3 is concentrated in brain tissues unlike JNK3 homologous heterologous proteins. Various studies have been conducted on the relationship between diseases of the nervous system.

JNK3 phosphorylates and activates amyloid precursor protein (APP), a major cause of Alzheimer's disease, places it in the cell membrane, promotes conversion to beta amyloid, and after beta amyloid is formed, its toxicity induces neuronal death. It has been reported that the activation of JNK3 is a major factor. In addition, a significant decrease in oligomeric beta amyloid and an increase in cognitive ability have been observed in the Familial Alzheimer's diseases (FAD) of mice with Alzheimer's disease (FAD). Acquisition of resistance to the side effects and the inhibitory effect on the glutamate analogue, a neurotoxic substance has been found.

Under these circumstances, as a novel substance for the treatment of degenerative neurological diseases, research on the discovery of JNK3 inhibitors has been actively conducted (Korean Patent Laid-Open No. 2001-0029352), but it is still inadequate.

One object of the present invention to solve the above problems is to provide a novel imidazole derivative having a JNK inhibitory activity, pharmaceutically acceptable salts thereof, optical isomers, hydrates or solvates thereof.

Another object of the present invention comprises a novel imidazole derivative having the JNK inhibitory activity, a pharmaceutically acceptable salt thereof, an optical isomer thereof, a hydrate or a solvate thereof as an active ingredient, the prevention or treatment of degenerative neurological disease It is to provide a pharmaceutical composition.

The novel imidazole derivatives having a JNK inhibitory activity of the present invention, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof are represented by the following general formula (1).

<Formula 1>

In Formula 1, Q represents N or CH;

R ₁ represents a C ₅ -C ₁₆ aryl group, a C ₄ -C ₁₀ heteroaryl group, a C ₃ -C ₁₀ cycloalkyl group or a C ₁ -C ₁₀ heterocycloalkyl group;

R ₂ is a hydrogen atom, a C ₁ -C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, C ₁ -C ₆ Alkoxy C ₁ -C ₆ alkyl group, -C (R _a R _b ) CN wherein R _a and R _b each independently represent a hydrogen atom, a C ₁ -C ₆ alkyl group or a halogen atom, a carboxyl group, a carboxylic acid C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, aminocarbonyl (-C (= 0 )-) Group, aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₂ -C ₁₂ dialkyl aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, amino C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino C ₁ -C ₆ alkyl group, C _1- C ₆ alkyl sulfinyl (-S (= O)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl sulfonyl (-S (= O) _2- ) C ₁ -C ₆ alkyl group, C ₃ -C ₁₀ cycloalkyl group, C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, C ₁ -C ₁₀ heterocycloalkyl C ₁ -C ₆ alkyl group, C ₅ -C ₈ aryl C ₁ -C ₆ alkyl group or C ₂ -C ₈ heteroaryl C ₁ -C ₆ alkyl group;

L is a single bond, a C ₅ -C ₁₀ arylene group, a C ₃ -C ₁₀ cycloalkylene group, a C ₂ -C ₈ heterocycloalkylene group or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C (= 0)-) group,

R ₃ represents a hydrogen atom, C ₁ -C ₆ alkyl group, hydroxy C ₁ -C ₆ alkyl group, C ₃ -C ₁₀ cycloalkyl group, C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, C ₁ -C ₁₀ hetero Cycloalkyl group, C ₁ -C ₁₀ heterocycloalkyl C ₁ -C ₆ alkyl group, C ₅ -C ₁₀ aryl group, C ₅ -C ₁₀ aryl C ₁ -C ₆ alkyl group, C ₅ -C ₁₀ heteroaryl group, C ₅ -C ₁₀ heteroaryl C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) group, C ₃ -C ₁₀ cycloalkyl carbonyl (-C (= 0)-) group, C ₃ -C ₈ heterocycloalkyl carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) group, C ₃ -C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group, C ₂ -C ₈ heterocycloalkyl amino carbonyl (-C (= 0) Group, C ₅ -C ₁₀ arylamino carbonyl (-C (= 0)-) group, C ₅ -C ₁₀ heteroaryl amino carbonyl (-C (= 0)-) group, C ₁ -C ₆ Alkyl sulfonyl (-S (= O) _2- ) groups, C ₃ -C ₈ cycloalkyl sulfonyl (-S (= O) _2- ) groups, C ₃ -C ₈ heterocycloalkyl sulfonyl (-S (= O) _2- ) group, C ₅ -C ₁₀ aryl sulfonyl (-S (= O) _2- ) group or C ₅ -C ₁₀ heteroaryl sulfonyl Represents a (-S (= 0) _2- ) group;

At least one or more of the hydrogen atoms included in R ₁ , R ₂ , L and R ₃ of Formula 1 may each independently be a halogen atom (F, Cl, Br, I), a C ₁ -C ₆ haloalkyl group, C _1- It may be unsubstituted or substituted with any one of a C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxyl group and an amino group. There is;

When R ₂ is —CH ₂ CN, L is a single bond, a C ₅ -C ₁₀ arylene group, a C ₂ -C ₈ heterocycloalkylene group or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C ( = 0)-) group, where

When L is a single bond, except when R ₃ is a C ₁ -C ₆ alkyl group,

When L is a C ₄ -C ₅ heterocycloalkylene group R ₃ is a C ₃ -C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl amino carbonyl (-C ( = 0)-) group or C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group.

The novel imidazole derivatives, pharmaceutically acceptable salts thereof, optical isomers, hydrates or solvates thereof of the JNK inhibitory activity of the present invention may be a compound selected from the group consisting of the following compounds.

(One) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl)- 1H-imidazol-5-yl) propanenitrile

(2) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl)- 1H-imidazol-5-yl) -2-methylpropannitrile

(3) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl)- 1H-imidazol-5-yl) acetamide

(4) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl ) -1H-imidazol-5-yl) acetamide

(5) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl)- 1H-imidazol-5-yl) -N, N-dimethylacetamide

(6) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl)- 1H-imidazol-5-yl) -2-methylpropanamide

(7) (S) -cyclopropyl (3-((4- (5-ethyl-2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine- 1-day) methanone

(8) (S) -cyclopropyl (3-((4- (5- (methoxymethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) Piperidin-1-yl) methanone

(9) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl ) -1H-imidazol-5-yl) acetic acid

10 (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl ) -1H-imidazol-5-yl)

(11) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl ) -1H-imidazol-5-yl) -2-fluoroacetamide

(12) (S) -2- (1- (2- (1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (2,3-dihydrobenzofuran -5-yl) -1H-imidazol-5-yl) acetonitrile

(13) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl ) -1H-imidazol-5-yl) propanenitrile

(14) (S) -cyclopropyl (3-((4- (2- (2,3-dihydrobenzofuran-5-yl) -5-((methylsulfonyl) methyl) -1H-imidazol-1-yl ) Pyrimidin-2-yl) amino) piperidin-1-yl) methanone

(15) (S) -cyclopropyl (3-((4- (5-((methylsulfonyl) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl ) Amino) piperidin-1-yl) methanone

(16) (S) -cyclopropyl (3-((4- (5- (methylsulfinyl) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidine-2 -Yl) amino) piperidin-1-yl) methanone

(17) (S) -1- (4- (5- (cyanomethyl) -2- (3,4-dichlorophenyl) -1H-imidazol-1-yl) pyrimidin-2-yl) -3- ( 1- (cyclopropanecarbonyl) piperidin-3-yl) urea

(18) (S) -cyclopropyl (3-((4- (5- (hydroxymethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl ) Amino) piperidin-1-yl) methanone

(19) (S) -ethyl 2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetate

20 (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl)- 1H-imidazol-5-yl) acetic acid

(21) (S) -3-((4- (5- (cyanomethyl) -2- (3,4-dichlorophenyl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino)- N-cyclopropylpiperidine-1-carboxamide

(22) (S) -N- (tert-butyl) -3-((4- (5- (cyanomethyl) -2- (3,4-dichlorophenyl) -1H-imidazol-1-yl) pyrimidine -2-yl) amino) piperidine-1-carboxamide

(23) (S) -cyclopropyl (3-((4- (5- (5- (morpholinomethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) Piperidin-1-yl) methanone

(24) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) azpan-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H Imidazol-5-yl) acetonitrile

(25) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) azetidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H Imidazol-5-yl) acetonitrile

(26) (S) -2- (1- (2-((1- (cyclopropylmethyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H Imidazol-5-yl) acetonitrile

(27) (S) -cyclopropyl (3-((4- (5-((dimethylamino) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl ) Amino) piperidin-1-yl) methanone

(28) 2- (1- (2-((3- (cyclopropanecarbonyl) phenyl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) aceto Nitrile

(29) Cyclopropyl (3-((4- (5- (methoxymethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) methanone

(30) (S) -2- (2- (3,4-dichlorophenyl) -1- (2-((1-pivaloylpiperidin-3-yl) amino) pyrimidin-4-yl) -1H- Imidazole-5-yl) acetonitrile

(31) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) pyrrolidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl)- 1H-imidazol-5-yl) acetonitrile

(32) (S) -2- (1- (2-((1- (cyclobutanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl)- 1H-imidazol-5-yl) acetonitrile

(33) (S) -2- (1- (2-((1- (cyclohexanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl)- 1H-imidazol-5-yl) acetonitrile

(34) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyridin-4-yl) -2- (3,4-di Chlorophenyl) -1H-imidazol-5-yl) acetonitrile.

A pharmaceutical composition for the prevention or treatment of degenerative neurological diseases for another object of the present invention is an imidazole derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, an optical isomer thereof, a hydrate or solvate thereof as an active ingredient. Include.

According to the novel imidazole derivative having a JNK inhibitory activity of the present invention described above, a pharmaceutically acceptable salt thereof, an optical isomer thereof, a hydrate or solvate thereof and a pharmaceutical composition comprising the same, the novel imide having a JNK inhibitory activity One imidazole derivative, pharmaceutically acceptable salt thereof, optical isomer thereof, hydrate or solvate thereof exhibits good inhibitory activity against JNK, and pharmaceutical compositions comprising the same are useful for the prevention and treatment of degenerative neurological diseases. It is available.

Hereinafter, the present invention will be described in detail.

The novel imidazole derivatives having a JNK inhibitory activity according to the present invention, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof are represented by the following general formula (1).

<Formula 1>

In Formula 1, Q represents N or CH;

R ₁ represents a C ₅ -C ₁₆ aryl group, a C ₄ -C ₁₀ heteroaryl group, a C ₃ -C ₁₀ cycloalkyl group or a C ₁ -C ₁₀ heterocycloalkyl group;

R ₂ is a hydrogen atom, a C ₁ -C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, C ₁ -C ₆ Alkoxy C ₁ -C ₆ alkyl group, -C (R _a R _b ) CN wherein R _a and R _b each independently represent a hydrogen atom, a C ₁ -C ₆ alkyl group or a halogen atom, a carboxyl group, a carboxylic acid C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, aminocarbonyl (-C (= 0 )-) Group, aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₂ -C ₁₂ dialkyl aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, amino C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino C ₁ -C ₆ alkyl group, C _1- C ₆ alkyl sulfinyl (-S (= O)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl sulfonyl (-S (= O) _2- ) C ₁ -C ₆ alkyl group, C ₃ -C ₁₀ cycloalkyl group, C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, C ₁ -C ₁₀ heterocycloalkyl C ₁ -C ₆ alkyl group, C ₅ -C ₈ aryl C ₁ -C ₆ alkyl group or C ₂ -C ₈ heteroaryl C ₁ -C ₆ alkyl group;

L is a single bond, a C ₅ -C ₁₀ arylene group, a C ₃ -C ₁₀ cycloalkylene group, a C ₂ -C ₈ heterocycloalkylene group or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C (= 0)-) group,

R ₃ represents a hydrogen atom, C ₁ -C ₆ alkyl group, hydroxy C ₁ -C ₆ alkyl group, C ₃ -C ₁₀ cycloalkyl group, C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, C ₁ -C ₁₀ hetero Cycloalkyl group, C ₁ -C ₁₀ heterocycloalkyl C ₁ -C ₆ alkyl group, C ₅ -C ₁₀ aryl group, C ₅ -C ₁₀ aryl C ₁ -C ₆ alkyl group, C ₅ -C ₁₀ heteroaryl group, C ₅ -C ₁₀ heteroaryl C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) group, C ₃ -C ₁₀ cycloalkyl carbonyl (-C (= 0)-) group, C ₃ -C ₈ heterocycloalkyl carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) group, C ₃ -C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group, C ₂ -C ₈ heterocycloalkyl amino carbonyl (-C (= 0) Group, C ₅ -C ₁₀ arylamino carbonyl (-C (= 0)-) group, C ₅ -C ₁₀ heteroaryl amino carbonyl (-C (= 0)-) group, C ₁ -C ₆ Alkyl sulfonyl (-S (= O) _2- ) groups, C ₃ -C ₈ cycloalkyl sulfonyl (-S (= O) _2- ) groups, C ₃ -C ₈ heterocycloalkyl sulfonyl (-S (= O) _2- ) group, C ₅ -C ₁₀ aryl sulfonyl (-S (= O) _2- ) group or C ₅ -C ₁₀ heteroaryl sulfonyl Represents a (-S (= 0) _2- ) group;

At least one or more of the hydrogen atoms included in R ₁ , R ₂ , L and R ₃ of Formula 1 may each independently be a halogen atom (F, Cl, Br, I), a C ₁ -C ₆ haloalkyl group, C _1- It may be unsubstituted or substituted with any one of a C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxyl group and an amino group. There is;

When R ₂ is —CH ₂ CN, L is a single bond, a C ₅ -C ₁₀ arylene group, a C ₂ -C ₈ heterocycloalkylene group or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C ( = 0)-) group, where

When L is a single bond, except when R ₃ is a C ₁ -C ₆ alkyl group,

When L is a C ₄ -C ₅ heterocycloalkylene group R ₃ is a C ₃ -C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl amino carbonyl (-C ( = 0)-) group or C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group.

In the present invention, "C _x " of the functional group indicates that x represents the number of carbons (C), and C _x -C _y means a functional group having more than x and not more than y.

Halogen atoms in the present invention are F, Cl, Br or I.

In the present invention, when R ₂ is -C (R _a R _b ) CN, "-C (R _a R _b ) CN" is _a monovalent functional group in which R _a , R _b and CN are each bonded to one carbon. It means (see formula 2).

In the present invention, “substituted with a substituent” is one in which a hydrogen atom is replaced by a substituent which is a non-hydrogen atom, and valence requirements must be satisfied and chemically stable compounds must be generated from substitution. Also, unless expressly stated to be “unsubstituted”, all functional groups are to be construed as capable of being substituted or unsubstituted.

In the present invention, an "alkyl group" means a linear saturated hydrocarbon group or a branched saturated hydrocarbon group, which is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl and the like. Alkyl groups may be attached to a parent group or substrate at any ring atom and may include one or more non-hydrogen substituents unless the attachment would violate valence requirements.

In the present invention, "C ₁ -C ₆ alkyl carbonyl (-C (= O) -) C 1 -C 6 alkyl group" is a C ₁ -C ₆ alkyl group in which one hydrogen atom is C ₁ -C ₆ alkylcarbonyl ( It is defined as meaning a functional group in the form substituted with a -C (= 0)-) group. Further, C ₁ -C ₆ alkoxy carbonyl C ₁ -C ₆ alkyl group, aminocarbonyl (-C (═O)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino carbonyl (-C (= O)-) C ₁ -C ₆ alkyl group, C ₂ -C ₁₂ dialkyl amino carbonyl (-C (= O)-) C ₁ -C ₆ alkyl group, amino C ₁ -C ₆ alkyl group, C ₁ -C ₆ Alkyl amino C ₁ -C ₆ alkyl groups, C ₁ -C ₆ alkyl sulfinyl (-S (= O)-) C ₁ -C ₆ alkyl groups, C ₁ -C ₆ alkyl sulfonyl (-S (= O) _2- ) C ₁ -C ₆ alkyl group, C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, C ₅ -C ₈ aryl C ₁ -C ₆ alkyl group, C ₂ -C ₈ heteroaryl C ₁ -C ₆ alkyl group and C _{Even in the 1} -C ₁₀ heterocycloalkyl C ₁ -C ₆ alkyl group, one hydrogen atom of the C ₁ -C ₆ alkyl group is an alkoxy carbonyl (-C (= O)-) group, an amino carbonyl group, an alkyl amino carbonyl (-C ( = O)-) group, dialkyl amino carbonyl (-C (= O)-) group, amino group, alkylamino group, alkyl sulfinyl group, alkylsulfonyl group, cycloalkyl group, aryl group, heteroaryl group and heterocycloal It means a functional group substituted with a group.

In the present invention, the "aryl group" also includes a structure in which a monocyclic aromatic or polycyclic aromatic and a saturated hydrocarbon ring are fused to a monocyclic or polycyclic aromatic. Aryl groups include phenyl group, naphthalenyl, tetrahydronaphthalenyl, biphenyl, anthracenyl, phenanthrenyl, pyrenyl and the like. The aryl group can be attached to the parent group or substrate at any ring atom and can include one or more non-hydrogen substituents if the attachment does not violate valence requirements.

In the present invention, "heteroaryl group" means a monocyclic or polycyclic hetero ring in which at least one carbon atom in the aryl group is substituted with nitrogen (N), oxygen (O) or sulfur (S). Heteroaryl groups are pyridinyl, furanyl, pyrrolyl, thiophenyl, thiazolyl, isothiazolyl, imidazolyl, triazolyl, tetrazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyridazinyl , Pyrimidinyl, isoquinolinyl, carbazolyl, benzooxazolyl, benzodioxyl, benzodioxazolyl, benzodioxylyl, benzothiazolyl, benzoimidazolyl, dihydrobenzothiophenyl, benzothiophenyl, Quinolinyl, indolyl, benzofuranyl, dihydrobenzofuranyl, purinyl, indolizinyl, chromanyl, chromanyl, dihydrobenzodioxinyl and the like. Heteroaryl groups can be attached to the parent group or substrate at any ring atom and include one or more non-hydrogen substituents unless the attachment would violate valence requirements.

In the present invention, "cycloalkyl group" means a saturated hydrocarbon ring generally having a specified number of carbon atoms including a ring, and a saturated hydrocarbon ring is meant to include both monocyclic and polycyclic rings. Cycloalkyl groups include cyclohexyl, cycloheptanyl, cyclooctanyl, tetrahydronaphthalenyl and the like. Cycloalkyl groups can be attached to the parent group or substrate at any ring atom and can include one or more non-hydrogen substituents unless the attachment would violate valence requirements.

In the present invention, "heterocycloalkyl group" means a monocyclic and polycyclic hetero ring containing 1 to 4 heteroatoms independently selected from nitrogen (N), oxygen (O) and sulfur (S). Heterocycloalkyl groups include tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl and the like. Heterocycloalkyl groups can be attached to the parent group or substrate at any ring atom and include one or more non-hydrogen substituents unless the attachment would violate valence requirements.

In the present invention, "alkoxy group" means -OR ', wherein R' represents an alkyl group, which is substantially the same as the alkyl group as defined above. Alkoxy groups include methoxy, ethoxy and the like. The alkoxy group can be attached to the parent group or substrate at any ring atom and can include one or more non-hydrogen substituents unless the attachment would violate valence requirements.

In the present invention, "carbonyl (-C (= O)-) group" means '-C (= O)-', wherein the substituents bonded to the carbon of the carbonyl group is alkyl, alkoxy, cycloalkyl, amino, etc. It is described with an alkyl carbonyl (-C (= O)-) group, an alkoxy carbonyl (-C (= O)-) group, a cycloalkyl carbonyl (-C (= O)-) group, and the like. At this time, the carbonyl (—C (═O) —) group may be attached to the parent group or the substrate at any ring atom if the attachment does not violate valence requirements, and may include one or more non-hydrogen substituents.

In the present invention, an alkyl carbonyl (-C (= 0)-) group, an alkoxy carbonyl (-C (= 0)-) group, an alkyl amino carbonyl (-C (= 0)-) group, a dialkyl amino group C _x -C _y defined in each carbonyl (-C (= O)-) group and the like means each carbon number such as an alkyl group, an alkoxy group, an alkylamino group and a dialkyl amino group which are substituents bonded to carbon of carbonyl. One carbon constituting the carbonyl group is defined as not being included in the x and y values of C _x -C _y .

In the present invention, "single bond" means that the carbon atom of R ₃ and the nitrogen atom of NH are directly bonded.

In the present invention, "C ₅ -C ₁₀ arylene group" means a divalent functional group derived from a C ₅ -C ₁₀ aryl group.

In the present invention, "cycloalkylene group" means a divalent functional group derived from cycloalkyl, and "heterocycloalkylene group" means a divalent functional group derived from heterocycloalkyl.

In the present invention, the "C ₃ -C ₈ heterocycloalkylene aminocarbonyl (-C (= 0)-) group" is derived from C ₃ -C ₈ heterocycloalkyl aminocarbonyl (-C (= 0)-) Means a divalent functional group.

The compounds of the present invention include not only pharmaceutically acceptable salts, but also all salts, isomers, hydrates and solvates that can be prepared by conventional methods.

As used herein, the term "optical isomer" includes both enantiomers as well as mixtures and racemates of the enantiomers.

Formula 1 of the present invention is a compound represented by the following formula 1-1, L represented by the formula (1-1) or a compound represented by the following formula (1-1 and 1) when L includes a subsidiary carbon of chiral center (chiral center) The mixture represented by -2 is mixed.

<Formula 1-1>

<Formula 1-2>

Q, R ₁ , R ₂ , L, and R ₃ in Chemical Formulas 1-1 and 1-2 are the same as defined in Chemical Formula 1.

Formula 1 of the present invention, when L is directly bonded to R ₃ and N as a single bond, when R ₃ comprises a subsidiary carbon chiral center (chiral center), represented by the following formula 1-3 It includes a compound, a compound represented by the following formula (1-4) or a mixture of the compound represented by the formula (1-3) and 1-4.

<Formula 1-3>

<Formula 1-4>

Q, R ₁ , R ₂ , L, and R ₃ in Chemical Formulas 1-3 and 1-4 are the same as defined in Chemical Formula 1.

A 'hydrate' of the present invention is a stoichiometric or non-stoichiometric amount in which water is bonded to imidazole derivative represented by Chemical Formula 1, a pharmaceutically acceptable salt thereof, or an optical isomer thereof, and the like with non-covalent intermolecular force. It may be to include the water. Specifically, the hydrate may include about 0.25 mol to about 10 mol of water based on 1 mol of the active ingredient, more specifically about 0.5 mol, about 1 mol, about 1.5 mol, about 2 mol, about 2.5 moles, about 3 moles, about 5 moles, and the like.

The 'solvate' of the present invention is that the imidazole derivative represented by the formula (1), a pharmaceutically acceptable salt thereof, or an optical isomer thereof and a solvent other than water are bonded by intermolecular force, the solvent is stoichiometric or non- It may include in stoichiometric amounts. Specifically, the solvate may include a solvent molecule in a ratio of about 0.25 mol to about 10 mol based on 1 mol of the active ingredient, and more specifically about 0.5 mol, about 1 mol, about 1.5 mol, and about 2 mol , About 2.5 moles, about 3 moles, about 5 moles, and the like.

In an embodiment, in Formula 1, R ₁ may be a C ₅ -C ₁₆ aryl group or a C ₄ -C ₁₀ heteroaryl group.

Specifically, in Formula 1, R ₁ is a phenyl group, naphthalenyl, tetrahydronaphthalenyl, biphenyl, anthracenyl, phenanthrenyl, pyrenyl, pyridinyl, furanyl, pyrrolyl, thiophenyl, thiazolyl, iso Thiazolyl, imidazolyl, triazolyl, tetrazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, isoquinolinyl, carbazolyl, benzoxazolyl, benzodioxolyl (1 , 3-benzodioxyl, 1,4-benzodioxyl, etc.), benzodioxyl, benzothiazolyl, benzoimidazolyl, benzothiophenyl, dihydrobenzothiophenyl, quinolinyl, indolyl, benzofuran 1, dihydrobenzofuranyl, purinyl, indolizinyl, chromanyl, chromanyl or dihydrobenzodioxinyl and the like. In this case, at least one or more hydrogen atoms included in R ₁ in Formula 1 may each independently represent a halogen atom (F, Cl, Br, I), a C ₁ -C ₆ haloalkyl group, a C ₁ -C ₆ alkyl group, C ₂ It may be unsubstituted or substituted with any one of a -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxy group and an amino group.

More specifically, in Formula 1, R ₁ is benzo-1,3-dioxoyl, dihydrobenzo-1,4-dioxinyl, dihydrobenzofuranyl, quinolinyl, naphthalenyl, dichlorophenyl, fluoro A (trifluoromethyl) phenyl group etc. can be shown.

In one embodiment, R ₂ of Formula 1 is a C ₁ -C ₆ alkoxy C ₁ -C ₆ alkyl group, -C (R _a R _b ) CN (wherein R _a and R _b are each independently a hydrogen atom, C ₁ -C ₆ alkyl group or halogen atom), C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0 )-) C ₁ -C ₆ alkyl group, aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) C _1- C ₆ alkyl group, C ₂ -C ₁₂ dialkyl amino carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, amino C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkylamino C ₁ -C ₆ Alkyl group, C ₁ -C ₆ alkyl sulfinyl (-S (= O)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl sulfonyl (-S (= O) _2- ) C ₁ -C ₆ alkyl group , C ₃ -C ₁₀ cycloalkyl group, C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, C ₁ -C ₁₀ heterocycloalkyl C ₁ -C ₆ alkyl group, C ₅ -C ₈ aryl C ₁ -C ₆ alkyl group Or a C ₂ -C ₈ heteroaryl C ₁ -C ₆ alkyl group. At least one or more of the hydrogen atoms included in R ₂ in Formula 1 may each independently represent a halogen atom (F, Cl, Br, I), a C ₁ -C ₆ alkyl group, C ₂ -C ₆ It may be unsubstituted or substituted with any one of an alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxy group and an amino group.

In an embodiment, when R ₂ in Formula 1 is —C (R _a R _b ) CN, R _a and R _b each independently represent a hydrogen atom, a C ₁ -C ₆ alkyl group, or a halogen atom, wherein R At least one of _a and R _b may be a C ₁ -C ₆ alkyl group or a halogen atom.

In an embodiment, when R ₁ of Formula 1 is a C ₄ -C ₁₀ heteroaryl group, and R ₂ is —C (R _a R _b ) CN, R _a and R _b are each independently a hydrogen atom, C _{It may be a 1} -C ₆ alkyl group or a halogen atom, in this case, both R _a and R _b may be a hydrogen atom. For example, when the R ₁ of Formula 1-dihydro-benzothiophen-yl, benzofuran-yl or dihydro-dihydro-benzo dioxin-yl and R ₂ is -C (R _a R _b) CN, R _a and R _b May be each independently a hydrogen atom, a C ₁ -C ₆ alkyl group or a halogen atom, in which case R _a and R _b may both be hydrogen atoms.

More specifically, in Formula 1, R ₂ is methoxycarbonylmethyl, -CHFCN, -CF ₂ CN, -CH (CH ₃ ) CN, -C (CH ₃ ) ₂ CN, aminocarbonylmethyl, aminocarbon Nyldihalomethyl, aminocarbonyl monohalomethyl, aminocarbonylethyl, methyl, ethyl, trihalomethyl, trihaloethyl, methoxyalkyl, methylaminocarbonylmethyl, dimethylaminocarbonylmethyl, p Rollylmethyl, pyrazolylmethyl, triazolylmethyl, methylaminomethyl, methylsulfonylmethyl and the like.

In one embodiment, L in Chemical Formula 1 is a single bond, a C ₅ -C ₁₀ arylene group, a C ₃ -C ₈ heterocycloalkylene aminocarbonyl (-C (= 0)-) group or cyclohexyl, cycloheptane Divalent substituents derived from one, cyclooctanyl, tetrahydronaphthalenyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl and the like. . At least one or more of the hydrogen atoms included in L in Formula 1 are each independently a halogen atom (F, Cl, Br, I), C ₁ -C ₆ alkyl group, C ₂ -C ₆ alkenyl group, C ₂ -C ₆ It may be unsubstituted or substituted with any one of an alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxy group and an amino group.

,

,

등일 수 있다.Specifically, L in Formula 1 may be a single bond, a C ₅ -C ₁₀ arylene group, a C ₃ -C ₈ heterocycloalkylene aminocarbonyl (-C (= 0)-) group, or

,

,

And the like.

인 경우, 상기 화학식 1, 1-1 또는 1-2로 표시되는 화합물은 각각 하기 화학식 1-5, 1-6 또는 1-7일 수 있다. For example, L is

In the case of, the compound represented by Formula 1, 1-1 or 1-2 may be the following Formula 1-5, 1-6 or 1-7, respectively.

<Formula 1-5>

<Formula 1-6>

<Formula 1-7>

In each of Formulas 1-5, 1-6, and 1-7, R ₁ , R _2, and R ₃ are substantially the same as defined in Formula 1, wherein * represents a subsidiary carbon which is a chiral center. Display.

In an embodiment, R ₃ of Formula 1 is a hydrogen atom, a hydroxy C ₁ -C ₆ alkyl group, a C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkylcar A carbonyl (-C (= 0)-) group, a C ₃ -C ₁₀ cycloalkyl group or a C ₃ -C ₁₀ cycloalkyl carbonyl (-C (= 0)-) group. In Formula 1, at least one or more of the hydrogen atoms included in R ₃ are each independently a halogen atom (F, Cl, Br, I), a C ₁ -C ₆ alkyl group, C ₂ -C ₆ It may be unsubstituted or substituted with any one of an alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxy group and an amino group.

More specifically, R ₃ may represent a hydrogen atom, hydroxy propyl, cyclopropanecarbonyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl or tert-butyloxycarbonyl and the like.

In one embodiment, the imidazole derivative represented by Formula 1, a pharmaceutically acceptable salt thereof, an optical isomer thereof, a hydrate or solvate thereof may include a compound represented by the following Formula 2.

<Formula 2>

In Formula 2, R ₁ , L and R ₃ are the same as in Formula 1, and R _a and R _b each independently represent a hydrogen atom, a C ₁ -C ₆ alkyl group or a halogen atom, R _a and R _b Except when simultaneously represents a hydrogen atom. In this case, at least one or more of the hydrogen atoms included in R ₁ , R _a , R _b , L and R ₃ of Formula 2 may each independently represent a halogen atom, a C ₁ -C ₆ haloalkyl group, a C ₁ -C ₆ alkyl group, It may be unsubstituted or substituted with any one of a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxyl group and an amino group.

In Formula 2, when R ₁ is a C ₄ -C ₁₀ heteroaryl group, both R _a and R _b may be hydrogen atoms. For example, when R ₁ of Formula 2 is dihydrobenzothiophenyl, dihydrobenzofuranyl or dihydrobenzodioxinyl, both R _a and R _b may be hydrogen atoms.

In one embodiment, the imidazole derivative represented by Formula 1, a pharmaceutically acceptable salt thereof, an optical isomer thereof, a hydrate or solvate thereof may include a compound represented by the following Formula 3.

<Formula 3>

In Formula 3, R ₁ and R ₃ are the same as in Formula 1, respectively, and R _c and R _d may each independently represent a hydrogen atom, a C ₁ -C ₆ alkyl group or a halogen atom.

In this case, at least one or more of the hydrogen atoms contained in R ₁ , R _c , R _d , L and R ₃ of Formula 3 are each independently a halogen atom, a C ₁ -C ₆ haloalkyl group, a C ₁ -C ₆ alkyl group, It may be unsubstituted or substituted with any one of a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxyl group and an amino group.

In one embodiment, the imidazole derivatives of Formula 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof may include compounds represented by the following Formulas 4 to 8.

<Formula 4>

<Formula 5>

<Formula 6>

<Formula 7>

<Formula 8>

In each of Formulas 4 to 8, R ₁ and R ₂ are the same as in Formula 1, respectively, and in Formula 8, R _e represents a C ₃ -C ₁₀ cycloalkyl group or a C ₁ -C ₆ alkoxy group.

In one embodiment, the compounds according to the invention can be prepared according to the following synthesis scheme 1.

Synthetic Scheme 1

In the synthesis scheme 1, R ₁ , R _a , R _b , L and R ₃ are the same as defined in Formula 1, OEt means O-ethylene.

In an embodiment, Compound B may be prepared by performing Step 1 on Compound A in Synthesis Scheme 1. The step 1 reaction includes dissolving Compound A in ethanol, then slowly adding acetyl chloride (AcCl) at 0 ° C., and stirring at room temperature for 24 hours to 48 hours, thereby obtaining Compound B. As a result of the reaction, after confirming that Compound A disappears completely by TLC, a process of concentrating in a vacuum and dilution with ether, separating the solid product, and washing it may be performed.

Compound 2 was obtained by performing step 2 on Compound B obtained through Step 1 in Synthesis Scheme 1. In step 2, Compound B and methanol dissolved in ammonia were mixed in ethanol, and the mixture was mixed at room temperature. It can be carried out by stirring for 12 hours.

Compound C and 1,3-dihydroxyacetone dimer, NH ₄ OH, and NH ₄ Cl obtained as a result of the step 2 reaction in Synthesis Scheme 1 were stirred at 80 ° C., to perform step 3 the compound C is then completely disappeared, the reaction mixture was cooled to room temperature and methylene chloride in TLC (CH ₂ Cl ₂₎ and then put separate the layers, filter the solid product produced in the organic layer, methylene chloride (CH ₂ Cl ₂ ) And crystallized to afford compound D.

Compound D obtained at this time is obtained by step 4 reaction. Specifically, the compound D is mixed with thionyl chloride and heated to 80 ° C. until the compound D disappears in TLC to terminate the reaction, and then cooled to room temperature, the solvent is removed in vacuo, and the compound obtained from Dimethyl sulfoxide is added to sodium cyanide and stirred at room temperature for 24 hours. After confirming the completion of the reaction, the reaction mixture was extracted with ethyl acetate (EtOAc), the organic layer was washed with water and brine, dried with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then column chromatography Compound E can be obtained by separation and purification by chromatography (EA: HEX = 1: 1).

Hexane-THF solvent (Base (NaH, n-BuLi)) containing tetrabutyldimethylsilyl chloride (TBDMS-Cl) was added to Compound E in Synthesis Scheme 1, and Selectfluor was added to the solution. Then (NaH, Selectflor, THF), tetrahydrofuran solvent containing tetrabutylammonium fluoride (TBAF) is added, and then separated and purified to obtain a compound F through a step 5 reaction. At this time, by adjusting the content of the select fluorine F may be introduced only in any one of R _a and R _b , or both R _a and R _b may be F.

Compound F was dissolved in anhydrous DMF in Synthesis Scheme 1, 0.5M KHMDS in toluene was added at 0 ° C., stirred at 0 ° C. for 30 minutes, and 4-chloro-2- (methylthio) pyrimidine (4-chloro After adding -2- (methylthio) pyrimidine) and stirring at 100 ° C. for 24 hours, cooling to room temperature, adding water, extracting the organic layer using ethyl acetate (EtOAc), and then washing the organic layer with water and brine. Then, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (EA: HEX = 1: 1) to obtain a compound G through a step 6 reaction.

Potassium peroxomonosulfate (Potassium peroxomonosulfate) for the compound G in the synthesis scheme 1 was mixed in a solvent mixed with methanol: water = 1: 1 (v: v), the mixture was stirred at room temperature for 1 hour and the After compound G disappears completely in TLC, the methanol is concentrated in vacuo, diluted with the addition of water to the concentrated mixture and stirred until the solid product is separated. The solid product can be filtered, washed sequentially with ether and hexane solvents and crystallized to afford compound H.

In one embodiment, the step 8 reaction in the synthesis scheme 1 may react the compound H with an amine compound of the R ₃ -L-NH ₂ form to prepare an imidazole derivative according to the present invention.

In another embodiment, the step 8 reaction in Synthesis Scheme 1 is obtained by reacting compound H with tert-butyl 3-aminopiperidine-1-carboxylate. The intermediate product represented by the formula (H-1) may be treated with 1,4-dioxane (1,4-dioxane) and HCl to prepare compounds having the structure of Formula ₂ wherein R ₂ is-(CR _a R _b ) CN. .

<Formula H-1>

In another embodiment, step 8 reaction in Synthesis Scheme 1 is obtained by reacting compound H with tert-butyl 3-aminopiperidine-1-carboxylate The intermediate product represented by Formula H-1 may be reacted with cycloalkane carbonyl chloride to prepare compounds having the structure of Formula 8 wherein R _e is a cycloalkyl group and R ₂ is-(CR _a R _b ) CN.

In one embodiment, the compounds according to the invention can be prepared according to the following synthetic scheme 2.

Synthesis Scheme 2

In the synthesis scheme 2, R ₁ , L and R ₃ are each substantially the same as defined in Formula 1, R _a and R _b each independently represent a hydrogen atom, a fluorine atom or a C ₁ -C ₆ alkyl group, At least one of R _a and R _b represents a fluorine atom or a C ₁ -C ₆ alkyl group.

In the above scheme 2, except that the introduction of R _a and R _b , which is _a hydrogen atom, a halogen atom or a C ₁ -C ₆ alkyl group, is carried out after the introduction of R ₃ -L-, up to the process of preparing compound E Substantially the same.

However, Compound E was reacted with 4-iodo-2- (methylthio) pyrimidine in Step 5 of Synthesis Scheme 2 to obtain Compound J, and Compound J was Compound K may be obtained by carrying out the step 6 reaction with potassium peroxomonosulfate. Thus obtained compound K is reacted with an amine compound of the form R ₃ -L-NH ₂ (step 7) to obtain compound L, and at least one of R _a and R _b using F source compound for compound L Can be introduced as a fluorine atom (step 8).

In one embodiment, the imidazole derivative represented by Formula 1, a pharmaceutically acceptable salt thereof, an optical isomer thereof, a hydrate or solvate thereof may include a compound represented by Formulas 17a and 17b.

<Formula 17a>

<Formula 17b>

In one embodiment, the compound represented by Formula 17a may be prepared through the following Synthetic Scheme 3.

Synthesis Scheme 3

In Synthesis Scheme 3, R ₁ is substantially the same as defined in Formula 1, any one of R _a and R _b is a hydrogen atom, and the other represents a C ₁ -C ₆ alkyl group. In addition, in the synthesis scheme 3, R _e represents a C ₃ -C ₁₀ cycloalkyl group or a C ₁ -C ₆ alkoxy group.

Specifically, the process for preparing compound J in the synthesis scheme 3 is substantially the same as described in the synthesis scheme 2. Therefore, redundant descriptions are omitted.

In Synthesis Scheme 3, either of Ra and Rb is introduced into an alkyl group using an alkyl source compound such as RX (R is a C ₁ -C ₆ alkyl group and X is a halogen atom) with respect to compound J (the other is hydrogen Atom). Compound N-1 can be obtained by reacting the obtained compound M-1 with potassium peroxomonosulfate. Compound N-1 is reacted with tert-butyl 3-aminopiperidine-1-carboxylate to give compound O-1, and 1,4-dioxane and HCl for compound O-1. Compound P-1 can be obtained by processing. Compound P-1 may be reacted with cycloalkane carbonyl chloride to finally obtain a compound according to one embodiment of the present invention. In the case of the compound represented by Formula 17a, any one of R _a and R _b is a hydrogen atom, the other represents a methyl group, and R _e represents a cyclopropyl group in the above-described Synthesis Scheme 3.

In one embodiment, the compound represented by Formula 17b may be prepared according to the following Scheme 4.

Synthetic Scheme 4

In the synthesis scheme 4, R ₁ is substantially the same as defined in Formula 1, R _a and R _b each independently represent a C ₁ -C ₆ alkyl group, wherein Ra and Rb may be the same or different from each other have. In addition, in the synthesis scheme 4, R _e represents a C ₃ -C ₁₀ cycloalkyl group or a C ₁ -C ₆ alkoxy group. In addition, in the synthesis scheme 4, Boc means tert-butyloxycarbonyl (tert-Butyloxycarbonyl).

Specifically, the process of preparing compound E in the synthesis scheme 4 is substantially the same as described in the synthesis scheme 1. Therefore, redundant descriptions are omitted.

In Synthesis Scheme 4, tert-butyloxycarbonyl was introduced to compound E using di-tert-butyl dicarbonate to obtain compound Q, and compound Q and alkyl source compound. Compound R can be obtained by introducing R _a and R _b using. Compound S is obtained by leaving tert-butyloxycarbonyl, a protecting functional group, from compound R.

Compound S-2 thus obtained can be reacted with 4-iodo-2- (methylthio) pyrimidine to yield compound M-2. In this case, Compound M-2 has the same chemical structure as Compound M-1 in Synthesis Scheme 3 except that both R _a and R _b are alkyl groups. The step of synthesizing Compound N-2, Compound O-2 and Compound P-2 sequentially by reacting using Compound M-2 is performed using Compound M-1 in Compound Synthesis Scheme 2 to synthesize Compound N-1 and Compound O. Since -1 and compound P-1 are substantially the same as the process of synthesizing sequentially, the overlapping detailed description is abbreviate | omitted.

In one embodiment, the imidazole derivative represented by Formula 1 of the present invention, a pharmaceutically acceptable salt thereof, an optical isomer thereof, a hydrate or solvate thereof may be represented by Formulas 18a, 18b, 18d, 18h, 20c, 20e, and 23a. Compounds represented by 23c, 24, 25, 27 and 28.

<Formula 18a>

<Formula 18b>

<Formula 18d>

<Formula 18h>

<Formula 20c>

<Formula 20e>

<Formula 23a>

<Formula 23b>

<Formula 23c>

<Formula 24>

<Formula 25>

<Formula 27>

<Formula 28>

In one embodiment, the imidazole derivative represented by Formula 1 of the present invention, a pharmaceutically acceptable salt thereof, an optical isomer thereof, a hydrate or solvate thereof may include a compound represented by the following Chemical Formulas 32 to 50.

<Formula 32>

<Formula 33>

<Formula 34>

<Formula 35>

<Formula 36>

<Formula 37>

<Formula 38>

<Formula 39>

<Formula 40>

<Formula 41>

<Formula 42>

<Formula 43>

<Formula 44>

<Formula 45>

<Formula 46>

<Formula 47>

<Formula 48>

<Formula 49>

<Formula 50>

In the present invention, “pharmaceutically acceptable” means a person of ordinary skill in the art, when physiologically acceptable and administered to humans, typically does not cause gastrointestinal disorders, allergic reactions such as dizziness or the like. It may mean a conventional use in the manufacture of a pharmaceutical formulation.

In the present invention, the pharmaceutically acceptable salts refer to non-toxic metal salts or salts prepared from organic bases.

As used herein, “salt” is an acid addition salt formed by a pharmaceutically acceptable free acid. Acid addition salts include inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid and aliphatic mono and dicarboxylates, phenyl-substituted alkanoates, hydroxy alkanoates and alkanediodes. Obtained from non-toxic organic acids such as acids, aromatic acids, aliphatic and aromatic sulfonic acids. Such pharmaceutically nontoxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide and iodide. Id, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suverate , Sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitro benzoate, hydroxybenzoate, meth Oxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chloro Benzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene- 1-sulfonate, naphthalene-2-sulfonate or mandelate.

The acid addition salts according to the invention are dissolved in conventional methods, for example, by dissolving the compound represented by the formula (1) in an excess of aqueous acid solution, and the salts are water miscible organic solvents such as methanol, ethanol, acetone or acetonite. It can be prepared by precipitation using a reel. It may also be prepared by evaporating the solvent or excess acid from the mixture and then drying or by suction filtration of the precipitated salt.

Bases may also be used to make pharmaceutically acceptable metal salts. Alkali metal or alkaline earth metal salts are obtained, for example, by dissolving a compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is pharmaceutically suitable to prepare sodium, potassium or calcium salt as the metal salt. Corresponding silver salts are obtained by reacting alkali or alkaline earth metal salts with a suitable negative salt (eg, silver nitrate).

On the other hand, the present invention comprises an imidazole derivative of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, a pharmaceutical composition for the prevention or treatment of degenerative neurological diseases, of the formula (1) for the treatment of the disease A method of treating such a disease comprising the use of an imidazole derivative or a pharmaceutically acceptable salt thereof, and administering to the subject a therapeutically effective amount of the compound of formula 1 or a pharmaceutically acceptable salt thereof.

As used herein, the term prophylaxis means any action that inhibits or delays the development of neurodegenerative neurological diseases by administration of the pharmaceutical composition according to the present invention.

As used herein, the term "treatment" means any action in which symptoms for degenerative neurological disease are improved or beneficially altered by administration of the pharmaceutical composition according to the present invention.

"Degenerative neurological disease", which is a disease to be prevented or treated by the composition of the present invention, may be included without limitation as long as it is a disease caused by brain injury, but may preferably be Alzheimer's, Parkinson's disease, Huntington's disease, multiple sclerosis or stroke. .

The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the active ingredient. At this time, the pharmaceutically acceptable carrier is commonly used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose , Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. In addition to the above components, it may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.

The pharmaceutical compositions of the invention may be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage may be determined by the condition and weight of the patient, Depending on the degree, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, the pharmaceutically effective amount means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to the medical treatment, and the effective dose level refers to the type of disease, the severity, the activity of the drug, and the drug. Sensitivity, time of administration, route of administration and rate of excretion, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical arts. The pharmaceutical compositions according to the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple administrations. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be readily determined by one skilled in the art.

Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, weight of the patient, the absorption of the active ingredient in the body, the inactivation rate and excretion rate, the type of disease, the drug used in general 0.001 to 160 mg, preferably 0.01 to 100 mg per kg of body weight can be administered daily or every other day, or divided into 1 to 3 times a day. However, the dosage may be increased or decreased depending on the route of administration, the severity of obesity, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.

In the present invention, "individual" means a subject to be treated for a disease, and more specifically, a mammal, such as a primate, a mouse, a dog, a cat, a horse, or a cow, which is human or non-human.

Hereinafter, preferred embodiments of the present invention will be described in order to help understanding of the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the following examples.

Production Example  (1-1) ethyl 2- Naphthyl imdate  Produce

2-naphthylyl (10 g, 65.3 mmol) was dissolved in ethanol (46 ml, 0.784 mol), and then acetyl chloride (AcCl, 37.3 ml, 0.522 mol) was slowly added at 0 ° C, and stirred at room temperature for 24 to 48 hours. It was. After 2-naphthylyl disappeared completely in TLC, it was concentrated in vacuo, and the concentrated mixture was diluted with ether and stirred until the solid product separated. The solid product was filtered and washed sequentially with ether and hexane solvents to give ethyl 2-naphthylimidate (yield 99%).

a white solid (99%); ¹ H NMR (400 MHz, DMSO) δ 8.90 (s, 1H), 8.14 (t, J = 3.9 Hz, 3H), 8.07 (d, J = 8.2 Hz, 1H), 7.79-7.73 (m, 1H), 7.67-7.72 (m, J = 8.1, 7.0, 1.2 Hz, 1H), 4.71 (q, J = 7.0 Hz, 2H), 3.70 (s, 1H), 1.53 (t, J = 7.0 Hz, 3H); LRMS (ESI) m / z calcd for C 13 H 13 NO [M + H] +: 200, Found 200.

Production Example  (1-2) 2- Of naphthylimideamide  Produce

Ethyl 2-naphthylimide (14.9 g, 63.1 mmol) obtained in Preparation Example (1-1) and methanol (63.1 ml) dissolved in 7N ammonia were mixed in ethanol (63.1 ml), and the mixture was Stir at room temperature for 12 hours. After ethyl 2-naphthylimide completely disappeared in TLC, it was concentrated in vacuo, and the concentrated mixture was diluted with ether and stirred until the solid product separated. The solid product was filtered off and washed sequentially with ether and hexane solvents to afford 2-naphthylimideamide, a crystallized compound.

a white solid (83%); ¹ H NMR (400 MHz, DMSO) δ 9.63 (s, 5H), 9.44 (s, 5H), 8.57 (d, J = 1.5 Hz, 3H), 8.15 (d, J = 8.7 Hz, 3H), 8.06- 8.10 (t, J = 8.4 Hz, 6H), 7.85-7.90 (dd, J = 8.6, 1.9 Hz, 3H), 7.66-7.75 (tdd, J = 14.6, 6.9, 1.4 Hz, 6H); LRMS (ESI) m / z calcd for C 11 H 11 N 2 [M + H] +: 207, Found 207.

Production Example  (1-3) Preparation of (2- (naphthalen-2-yl) -1H-imidazol-5-yl) methanol

2-naphthylimide amide (12.9 g, 76 mmol) and 1,3-dihydroxyacetone dimer (1.3-Dihydroxyacetone Dimer, 15.06 g, 83.6 mmol) obtained in Preparation Example (1-2), 28% NH ₄ OH (30.4 ml), NH ₄ Cl (21.1 g, 0.395 mol) were stirred at 80 ° C. for 2 hours. After 2-naphthylimideamide disappeared completely in TLC, the reaction mixture was cooled to room temperature and methylene chloride (CH ₂ Cl ₂ ) was added to separate the layers. The resulting solid product in the organic layer was filtered, washed with methylene chloride (CH ₂ Cl ₂ ) and crystallized to give (2- (naphthalen-2-yl) -1H-imidazol-5-yl) methanol.

a white solid (50%); ¹ H NMR (400 MHz, DMSO) δ 12.56 (s, 1H), 8.44 (s, 1H), 8.10 (dd, J = 8.6, 1.3 Hz, 1H), 7.96 (d, J = 8.7 Hz, 1H), 7.94-7.89 (m, J = 6.1 Hz, 2H), 7.58-7.46 (m, J = 6.8, 1.4 Hz, 2H), 7.06 (s, 1H), 4.98 (s, 1H), 4.47 (d, J = 5.3 Hz, 2H); LRMS (ESI) m / z calcd for C 14 H 12 N 2 O [M + H] +: 225, Found 225.

Production Example  (1-4) 2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) Acetonitrile  Produce

Thionyl chloride (52 ml, 0.71 mol) was mixed with (2- (naphthalen-2-yl) -1H-imidazol-5-yl) methanol (15.8 g, 71 mmol) obtained in Preparation Example (1-3). Heated to 80 ° C. until (2- (naphthalen-2-yl) -1H-imidazol-5-yl) methanol disappeared in TLC. After the reaction was completed, the reaction mixture was cooled to room temperature and the solvent was removed in vacuo, and dimethyl sulfoxide (355 ml) was added to the compound and sodium cyanide (17.4 g, 0.355 mol). Stirred for 24 h. After confirming the completion of the reaction, the reaction mixture was extracted with ethyl acetate (EtOAc), and then the organic layer was washed with water and brine, after which water was removed with anhydrous magnesium sulfate (MgSO ₄ ) and the solvent was evaporated. Separation and purification by column chromatography (EA: HEX = 1: 1) gave 2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile.

a yellow solid (74%); ¹ H NMR (400 MHz, DMSO) δ 12.76 (s, 1H), 8.46 (s, 1H), 8.09 (dd, J = 8.6, 1.6 Hz, 1H), 7.99 (d, J = 9.0 Hz, 1H), 7.97-7.90 (m, 2H), 7.59-7.49 (m, 2H), 7.27 (s, 1H), 3.95 (s, 2H); LRMS (ESI) m / z calcd for C 15 H 11 N 3 [M + H] +: 234, Found 234.

Production Example  (1-5) 2- (1- (2- ( Methylthio Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile

2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile (0.1 g, 0.429 mmol) obtained in Preparation Example (1-4) was anhydrous DMF (2 ml, 0.2 M). ), 0.5M KHMDS in toluene (0.94ml, 0.472mmol) was added slowly at 0 ° C. After stirring for 30 minutes at 0 ° C, 4-chloro-2- (methylthio) pyrimidine (4-chloro-2- (methylthio) pyrimidine, 0.05ml, 0.429mmol) was added slowly and stirred at 100 ° C for 24 hours. . After cooling to room temperature, water was added, the organic layer was extracted with ethyl acetate (EtOAc), and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (EA: HEX = 1: 1) to prepare 2- (1- (2- (methylthio) pyri). Midin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile.

a yellow solid (27%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.33 (d, J = 5.4 Hz, 1H), 8.05 (s, 1H), 7.88 (dd, J = 7.0, 1.6 Hz, 2H), 7.85 (s, 1H) , 7.80 (s, 1H), 7.60-7.52 (m, 2H), 7.42 (dd, J = 8.5, 1.7 Hz, 1H), 6.51 (d, J = 5.4 Hz, 1H), 3.88 (d, J = 0.9 Hz, 2H), 2.43 (s, 3H); LRMS (ESI) m / z calcd for C 20 H 15 N 5 S [M + H] +: 358, Found 358.

Production Example  (1-6) 2- (1- (2- ( Methylsulfonyl Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile

2- (1- (2- (methylthio) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) obtained in Preparation Example (1-5) Acetonitrile (0.13 g, 0.364 mmol) and potassium peroxomonosulfate (0.56 g, 1.82 mmol) were mixed in a solvent (2 ml) mixed with methanol: water = 1: 1 and the mixture was room temperature Stirred for 1 h. After 2- (1- (2- (methylthio) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile disappeared completely from TLC, vacuum Methanol was concentrated in. To the concentrated mixture was added water, diluted and stirred until the solid product separated. The solid product was filtered off, washed sequentially with ether and hexane solvents and crystallized to give 2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl)- 1H-imidazol-5-yl) acetonitrile was obtained.

a yellow solid (86%); ¹ H NMR (400 MHz, DMSO) δ 9.05 (d, J = 5.6 Hz, 1H), 8.17 (d, J = 1.4 Hz, 1H), 8.03 (s, 1H), 8.01-7.97 (m, J = 5.1 , 4.0 Hz, 2H), 7.96 (d, J = 8.6 Hz, 1H), 7.63 (d, J = 5.6 Hz, 1H), 7.61-7.54 (m, 3H), 4.10 (d, J = 0.8 Hz, 2H ), 3.02 (s, 3 H); LRMS (ESI) m / z calcd for C 20 H 15 N 5 O 2 S [M + H] +: 390, Found 390.

Production Example  (1-7) tert -Butyl (S) -3- (4- (5- ( Cyanomethyl Preparation of) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-ylamino) piperidine-1-carboxylate

2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl obtained in Preparation Example (1-6) Acetonitrile (0.874 g, 2.24 mmol) and tert-butyl (S) -3-aminopiperidine-1-carboxylate (0.9 g, 4.49 mmol) (22.4 ml, 0.1M) was stirred at 60 ° C. for 5 hours. 2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile disappears completely, then reaction mixture Was cooled to room temperature and concentrated in vacuo. The concentrated mixture was separated and purified by column chromatography (EA: Hex = 1: 1) to obtain tert-butyl (S) -3- (4- (5- (cyanomethyl) -2- (naphthalene-2-) Il) -1H-imidazol-1-yl) pyrimidin-2-ylamino) piperidine-1-carboxylate was obtained.

a yellow solid (88%); ¹ H NMR (400 MHz, MeOD) δ 8.17 (s, 1H), 7.99 (s, 1H), 7.88-7.85 (m, 2H), 7.81 (dd, J = 20.8 Hz, 2H), 7.56-7.49 (m , 2H), 7.39 (s, 1H), 6.47 (d, 1H), 3.91 (s, 2H), 3.79-3.56 (m, 1H), 3.55-3.33 (m, J = 39.4 Hz, 1H), 3.03- 2.67 (m, 2H), 2.02-1.97 (m, J = 7.0, 3.3 Hz, 1H), 1.38 (s, 9H), 1.34-1.26 (m, 4H), 0.97-0.70 (m, 1H); LRMS (ESI) m / z calcd for C 29 H 31 N 7 O 2 [M + H] +: 510, Found 510.

Production Example  (1-8) (S) -2- (2- (naphthalen-2-yl) -1- (2- (piperidine-3- Monoamino Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile

Tert-butyl (S) -3- (4- (5- (cyanomethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) obtained in Preparation Example (1-7). 1.29 g, 2.53 mmol of pyrimidin-2-ylamino) piperidine-1-carboxylate are dissolved in 25 ml of 1,4-dioxane and 4M-HCl ( 13 ml), and the reaction mixture is stirred at room temperature for 20 minutes. Ether was added to the mixture, diluted and stirred until the solid product separated. The solid product was filtered off, washed sequentially with ether and hexane solvents and crystallized to give (S) -2- (2- (naphthalen-2-yl) -1- (2- (piperidin-3-ylamino ) Pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile.

a white solid (89%); ¹ H NMR (400 MHz, MeOD) δ 8.15 (s, 1H), 7.92 (s, 1H), 7.88-7.77 (m, 4H), 7.52-7.44 (m, 2H), 7.36 (d, J = 8.3 Hz , 1H), 6.20 (d, J = 93.0 Hz, 1H), 3.91 (s, 2H), 3.62 (s, 1H), 3.21-3.05 (m, 2H), 2.90-2.73 (m, 2H), 2.05- 1.90 (m, J = 25.3 Hz, 1 H), 1.83-1.56 (m, 2H), 1.52-1.25 (m, 3H); LRMS (ESI) m / z calcd for C 24 H 23 N 7 [M + H] +: 418, Found 418.

Production Example  (1-9) (S) -2- (1- (2- (1- ( Cyclopropanecarbonyl Piperidine-3- Monoamino Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile

(S) -2- (2- (naphthalen-2-yl) -1- (2- (piperidin-3-ylamino) pyrimidin-4-yl) obtained in Preparation Example (1-8) 3.13 g, -1 H-imidazol-5-yl) acetonitrile, 7.02 mmol was cooled in THF (66 ml) to 0 ° C. and treated with TEA (1.84 ml, 1.22 mmol). Cyclopropanecarbonyl chloride (0.6 ml, 7.02 mmol) was added to the mixture at 0 ° C., which was stirred for 1 hour at room temperature. The reaction mixture was concentrated in vacuo, then diluted with methylene chloride and washed with water and saturated aqueous sodium chloride solution. The organic layer was dried with sodium sulfate, concentrated in vacuo, separated and purified by column chromatography (DCM: MEOH = 40: 1, DCM is dichloromethane (CH ₂ Cl ₂ ) and MeOH is methanol). S) -2- (1- (2- (1- (cyclopropanecarbonyl) piperidin-3-ylamino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imi Dazol-5-yl) acetonitrile was prepared.

a yellow solid (58%); ¹ H NMR (400 MHz, MeOD) δ 8.23 (d, J = 42.0 Hz, 1H), 7.99 (d, J = 5.5 Hz, 1H), 7.92-7.81 (m, J = 11.6, 8.5 Hz, 3H), 7.71 (s, 1H), 7.56-7.48 (m, 2H), 7.37 (d, J = 7.2 Hz, 1H), 6.53 (d, J = 56.5 Hz, 1H), 3.91 (s, 2H), 3.86 (s , 1H), 2.92-2.68 (m, J = 29.7, 20.7 Hz, 2H), 1.88-1.81 (m, J = 7.3, 2.8 Hz, 1H), 1.64-1.50 (m, 2H), 0.98-0.83 (m , 4H), 0.82-0.64 (m, 4H), 0.61-0.51 (m, J = 8.2 Hz, 1H); LRMS (ESI) m / z calcd for C 28 H 27 N 7 O [M + H] +: 478, Found 478.

Example 1: Preparation of Compound 17a (see Formula 17a)

(3-1) (1- (2- ( Methylthio Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) propanenitrile

2- (1- (2- (methylthio) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) aceto obtained in Preparation Example (1-5) Nitrile (194 mg, 0.543 mmol) was dissolved in anhydrous THF (1.09 ml, 0.5 M) and NaH 60% dispersion in mineral oil (26 mg, 0.652 mmol) was added at 0 ° C. After stirring at 0 ° C. for 30 minutes, MeI (40.6 μl, 0.652 mmol) was slowly added to the mixture and stirred at 0 ° C. again for 1 hour. After the reaction was terminated, water was added and the organic layer was extracted using ethyl acetate (EtOAc), and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (EA: HEX = 1: 3) to purify 2- (1- (2- (methylthio) pyri). Midin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) propannitrile was obtained.

a yellow oil (17%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.36 (d, J = 5.4 Hz, 1H), 8.14 (s, 1H), 7.87 (dd, J = 9.1, 2.9 Hz, 3H), 7.79 (d, J = 0.9 Hz, 1H), 7.61-7.53 (m, 2H), 7.43 (dd, J = 8.5, 1.8 Hz, 1H), 6.51 (d, J = 5.4 Hz, 1H), 4.19 (q, J = 7.2 Hz, 1H), 2.46 (s, 3H), 1.83 (d, J = 7.2 Hz, 3H); LRMS (ESI) m / z calcd for C 20 H 15 N 5 S [M + H] +: 372, Found 372.

(3-2) 2- (1- (2- ( Methylsulfonyl Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) propanenitrile

2- (1- (2- (methylthio) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl obtained in (3-1) of Example 1 above Propane nitrile (52.5 mg, 0.141 mmol) and methanol (1.74 ml) are premixed, and potassium peroxomonosulfate (435 mg, 0.707 mmol) is separated from water (1.74 ml, 1 ml per 0.25 g of oxone). It was added slowly after mixing. The mixture was stirred at rt for 1 h. After 2- (1- (2- (methylthio) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) propannitrile disappeared completely from TLC, vacuum Concentrated at. The mixture was extracted with an organic layer using water and ethyl acetate (EtOAc), and then the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), and the solvent was evaporated to thereby remove 2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H. -Imidazol-5-yl) propannitrile was obtained.

(3-3) tert -Butyl (S) -3- (4- (5- ( Cyanoethyl ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-ylamino) piperidine-1-carboxylate

2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazole-5- obtained in (3-2) of Example 1 above I) propanenitrile (55.2 mg, 0.137 mmol) and tert-butyl (S) -3-aminopiperidine-1-carboxylate (53.8 μl, 0.274 mmol) Stir at THF (1.37 ml, 0.1M) at 60 ° C. for 12 h. After the 2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) propannitrile disappears completely, the reaction mixture Was cooled to room temperature and concentrated in vacuo. The concentrated mixture was separated and purified by column chromatography (EA: Hex = 2: 3), tert-butyl (S) -3- (4- (5- (cyanoethyl) -2- (naphthalene-2-) Il) -1H-imidazol-1-yl) pyrimidin-2-ylamino) piperidine-1-carboxylate was obtained.

a yellow oil (98%); LRMS (ESI) m / z calcd for C 29 H 31 N 7 O 2 [M + H] +: 524, Found 524.

(3-4) (S) -2- (2- (naphthalen-2-yl) -1- (2- (piperidine-3- Monoamino Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) propanenitrile

Tert-butyl (S) -3- (4- (5- (cyanoethyl) -2- (naphthalen-2-yl) -1H-imidazole-1- obtained in (3-3) of Example 1) I) pyrimidin-2-ylamino) piperidine-1-carboxylate (72.2 mg, 0.138 mmol) is dissolved in 1,4-dioxane (1.38 ml, 0.1M) and 4M-HCl in 1,4-dioxane After treatment with (0.345 ml, 1.38 mmol), the reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, it was concentrated in vacuo. The concentrated mixture was diluted by addition of ether, the solid product was separated and the solid product was filtered, washed sequentially with ether and hexane solvent and crystallized to give (S) -2- (2- (naphthalen-2-yl)- 1- (2- (piperidin-3-ylamino) pyrimidin-4-yl) -1H-imidazol-5-yl) propannitrile was obtained.

(3-5) (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl Preparation of) Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) propanenitrile

2- (2- (naphthalen-2-yl) -1- (2- (piperidin-3-ylamino) pyrimidin-4-yl) -1H- obtained in (3-4) of Example 1 above Imidazol-5-yl) propannitrile (58.4 mg, 0.138 mmol) is dissolved in anhydrous THF (1.38 ml, 0.1 M) and (1- (cyclopropanecarbonyl) piperidin-3-yl) carbamate (12.5 μl, 0.138 mmol) and TEA (28.8 μl, 0.207 mmol) were added at 0 ° C. and stirred for 1 h. After the reaction was completed, the mixture was concentrated in vacuo and the mixture was extracted with water and dichloromethane (CH ₂ Cl ₂ ), and then the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (EA: Hex = 3: 1) to obtain (S) -2- (1- (2- ( (1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) propanenitrile Obtained.

a yellow oil (40%); ¹ H NMR (400 MHz, MeOD) δ 8.28 (d, J = 36.5 Hz, 1H), 8.06 (s, 1H), 8.01-7.70 (m, 4H), 7.64-7.52 (m, 2H), 7.44 (d , J = 7.7 Hz, 1H), 6.62 (d, J = 71.6 Hz, 1H), 4.23 (q, J = 7.2 Hz, 1H), 3.86 (dd, J = 47.0, 18.6 Hz, 2H), 3.23-2.34 (m, 3H), 1.89 (d, J = 17.1 Hz, 1H), 1.76 (d, J = 7.1 Hz, 3H), 1.68-1.30 (m, 3H), 1.09-0.53 (m, 5H); LRMS (ESI) m / z calcd for C 30 H 31 N 7 O [M + H] +: 492, Found 492.

Example 2: Preparation of Compound 17b (see Formula 17b)

(4-1) tert -Butyl 5- ( Cyanomethyl ) -2- (naphthalen-2-yl) -1H-imidazole-1- Carboxylate  Produce

2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile (8.7 g, 37.3 mmol) obtained in Preparation Example (1-4) was dissolved in methylene chloride, and then triethyl An amine (10.4ml, 37.3mmol), di-tert-butyl dicarbonate (di-tert-butyl dicarbonate, 18ml, 74.6mmol) and DMAP (4.5g, 36.8mmol) were added thereto and stirred at room temperature for 24 hours. After the reaction was completed, it was concentrated, separated by column chromatography, and purified to give tert-butyl 5- (cyanomethyl) -2- (naphthalen-2-yl) -1H-imidazole-1-carboxylate.

yellow gum (82.8%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.06 (d, J = 1.6 Hz, 1H), 7.9z0-7.84 (m, 3H), 7.61-7.57 (m, 2H), 7.54-7.50 (m, 2H) , 3.76 (d, J = 1.2 Hz, 2H), 1.40 (s, 9H).

(4-2) tert -Butyl 5- (2- Cyanopropane Preparation of 2-yl) -2- (naphthalen-2-yl) -1H-imidazole-1-carboxylate

Tert-butyl 5- (cyanomethyl) -2- (naphthalen-2-yl) -1H-imidazole-1-carboxylate (7.7 g, 23.1 mmol) obtained in Example 4 (4-1) was prepared. After dissolving in DMF (77ml, 0.3M) was added NaH (2.0g, 46.2mmol) at 0 ℃ and stirred for 30 minutes. Then CH ₃ I (2.9ml, 46.2mmol) was added and stirred at room temperature. After the reaction was completed, water was added, extracted with EA, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography, tert-butyl 5- (2-cyanopropan-2-yl) -2- (naphthalene- 2-yl) -1H-imidazole-1-carboxylate was obtained.

a white solid (57.8%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.08-8.06 (m, 1H), 7.90-7.84 (m, 3H), 7.59 (dd, J = 8.5, 1.8 Hz, 1H), 7.53-7.49 (m, 3H ), 1.78 (s, 6H), 1.38 (d, J = 2.5 Hz, 9H).

(4-3) 2- methyl -2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) Propanenitrile  Produce

Obtained in (4-2) of Example 2 above tert-Butyl 5- (2-cyanopropan-2-yl) -2- (naphthalen-2-yl) -1H-imidazole-1-carboxylatecarboxylate (5.3g, 14.66mmol) to methylenechloride (50ml , 0.3M) was added and TFA (11.8ml) and stirred for 24 hours. After the reaction was completed, it was concentrated, separated by column chromatography, and purified to give 2-methyl-2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) propannitrile.

¹ H NMR (400 MHz, DMSO) δ 8.56 (s, 1H), 8.09 (d, J = 1.3 Hz, 2H), 8.05-7.95 (m, 2H), 7.61 (ddd, J = 6.8, 6.1, 3.6 Hz , 3H), 2.08 (s, 1 H), 1.75 (d, J = 20.1 Hz, 6 H); LRMS (ESI) m / z calcd for C 17 H 15 N 3 [M + H] +: 262, Found 262.

(4-4) 2- methyl -2- (1- (2- ( Methylthio Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) propanenitrile

2-Methyl-2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) propannitrile (0.1 g, 0.38 mmol) obtained in Example 4 (4-3) was used as DMF. (1.3ml, 0.3M) and then 4-chloro-2- (methylthio) pyrimidine (4-chloro-2- (methylthio) pyrimidine, 0.05ml, 0.46mmol), Cs ₂ CO ₃ (0.25g, 0.76 mmol) and CuI (1 mg, 0.0038 mmol) were added, followed by stirring at 150 ° C. for 1 hour. After cooling to room temperature, water was added, the organic layer was extracted with ethyl acetate (EtOAc), and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (EA: HEX = 1: 5), followed by purification by 2-methyl-2- (1- (2- ( Methylthio) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) propannitrile was obtained.

Yellow gum (65.5%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.30 (d, J = 5.4 Hz, 1H), 8.06 (s, 1H), 7.85 (d, J = 8.1 Hz, 3H), 7.73 (s, 1H), 7.55 (dd, J = 6.1, 3.2 Hz, 2H), 7.47-7.41 (m, 1H), 6.46 (d, J = 5.4 Hz, 1H), 2.44 (s, 3H), 1.83 (s, 6H).

(4-5) 2- methyl -2- (1- (2- ( Methylsulfonyl Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) propanenitrile

Example 4 above instead of 2- (1- (2- (methylthio) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile 2-methyl-2- (1- (2- (methylthio) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) obtained in (4-4) Except for using propanenitrile, the same process as in Preparation Example (1-6) was carried out to yield 2-methyl-2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2 -(Naphthalen-2-yl) -1H-imidazol-5-yl) propannitrile was prepared.

white foam (68.6%); ¹ H NMR (300 MHz, DMSO) δ 9.04 (d, J = 5.5 Hz, 1H), 8.12 (s, 1H), 8.02 (s, 1H), 7.99-7.88 (m, 3H), 7.66 (d, J = 5.5 Hz, 1H), 7.60-7.47 (m, 3H), 2.91 (s, 3H), 1.73 (s, 6H).

(4-6) tert -Butyl (S) -3-((4- (5- (2- Cyanopropane Preparation of -2-yl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate

Example 2, instead of 2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile 2-methyl-2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazole-5- obtained from (4-5) Except for using propanenitrile, tert-butyl (S) -3-((4- (5- (2-cyanopropan-2-yl) was carried out in the same manner as in Preparation Example (1-7). ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate was prepared.

white foam (97.1%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.09 (d, J = 5.2 Hz, 1H), 8.07 (d, J = 1.3 Hz, 1H), 7.88-7.79 (m, 3H), 7.67 (s, 1H) , 7.57-7.48 (m, 2H), 7.45 (d, J = 8.5 Hz, 1H), 6.09 (s, 2H), 5.29 (d, J = 6.2 Hz, 1H), 3.97 (s, 1H), 3.75 ( s, 1H), 3.72 (s, 2H), 3.57 (s, 2H), 3.39 (s, 2H), 1.83 (s, 6H), 1.77 (s, 2H), 1.59 (s, 2H), 1.43 (s , 9H).

(4-7) (S) -2- methyl -2- (2- (naphthalen-2-yl) -1- (2- (piperidine-3- Monoamino Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) propanenitrile

Tert-butyl (S) -3-((4- (5- (2-cyanopropan-2-yl) -2- (naphthalen-2-yl) -2-) obtained in (4-6) of Example 2 above- 1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate (3.0 g, 5.58 mmol) was dissolved in methylene chloride (19 ml, 0.3 M) followed by TFA (2.1 ml, 27.9 mmol) was added and stirred at room temperature for 2 hours 30 minutes. The reaction mixture was concentrated in vacuo and separated and purified by column chromatography (MC: MeOH = 10: 1) to give (S) -2-methyl-2- (2- (naphthalen-2-yl) -1- (2- (Piperidin-3-ylamino) pyrimidin-4-yl) -1H-imidazol-5-yl) propannitrile was obtained.

98.4%; ¹ H NMR (400 MHz, CDCl ₃ ) δ 9.17 (s, 1H), 8.02 (s, 2H), 7.85-7.77 (m, 3H), 7.61 (s, 1H), 7.55-7.46 (m, 2H), 7.41 (dd, J = 8.5, 1.5 Hz, 1H), 6.63 (s, 1H), 6.13 (s, 1H), 3.45 (d, J = 11.0 Hz, 3H), 3.02 (s, 3H), 1.79 (s , 6H), 1.69 (s, 3H).

(4-8) (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl Preparation of) Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) -2-methylpropannitrile

(S) -2- (2- (naphthalen-2-yl) -1- (2- (piperidin-3-ylamino) pyrimidin-4-yl) -1H-imidazol-5-yl) aceto Instead of nitrile, (S) -2-methyl-2- (2- (naphthalen-2-yl) -1- (2- (piperidine-3-) obtained in (4-7) of Example 2 above Except for using monoamino) pyrimidin-4-yl) -1H-imidazol-5-yl) propannitrile, the same process as in Preparation Example (1-9) was carried out to give (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazole-5 -Yl) -2-methylpropanenitrile was prepared.

white foam (68%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.06 (s, 2H), 7.91-7.78 (m, 3H), 7.59-7.49 (m, 2H), 7.44 (d, J = 8.6 Hz, 1H), 6.08 ( s, 1H), 5.68 (s, 1H), 4.14 (d, J = 5.9 Hz, 1H), 3.76 (s, 1H), 3.39 (s, 4H), 1.83 (s, 6H), 1.79-1.54 (m , 4H), 1.05-0.98 (m, 1H), 0.89 (ddd, J = 11.2, 7.0, 4.0 Hz, 1H), 0.83-0.52 (m, 2H); LRMS (ESI) m / z calcd for C 30 H 31 N 7 O [M + H] +: 506, Found 506.

Example 3: Preparation of Compound 18a (Formula 18a)

(S) -2- (1- (2- (1- (cyclopropanecarbonyl) piperidin-3-ylamino) pyrimidin-4-yl) -2 obtained in Preparation Example (1-9) -2 -(Naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile (0.1 g, 0.209 mmol) was dissolved in DMSO (5 ml) and then K ₂ CO ₃ (0.04 g, 0.356 mmol) at 0 ° C. And 30% H ₂ O ₂ solution (0.064ml, 0.628mmol) was added and stirred at room temperature for 24 hours. After the reaction was completed, water was added, extracted with EA, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (S) -2- (1- (2-((1- (cyclopropanecarbonyl)). Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetamide was obtained.

a yellow solid (42%); ¹ H NMR (400 MHz, MeOD) δ 8.24 (d, J = 26.2 Hz, 1H), 8.02 (s, 1H), 7.94-7.82 (m, 3H), 7.67 (d, J = 28.6 Hz, 1H), 7.55 (m, 2H), 7.41 (d, J = 7.6 Hz, 1H), 6.59 (d, J = 37.6 Hz, 2H), 4.11 (s, 1H), 3.82 (s, 2H), 2.77 (s, 4H ), 1.87 (s, 1 H), 1.62 (s, 1 H), 1.34 (m, 3 H), 0.77 (m, 6 H); LRMS (ESI) m / z calcd for C 28 H 29 N 7 O 2 [M + H] +: 496, Found 496.

Example 4: Preparation of Compound 18b (Formula 18b)

(6-1) ethyl 3,4- Of dichlorobenzimidate  Produce

Ethyl 3,4-dichlorobenzimidate was prepared by substantially the same process as Preparation Example (1-1), except that 3,4-dichlorophenyl was used instead of naphthylyl.

a white solid (99%); ¹ H NMR (400 MHz, DMSO) δ 8.41 (s, 1H), 8.06 (d, J = 8.0 Hz, 1H), 7.93 (d, J = 8.2 Hz, 1H), 4.60 (q, J = 6.4 Hz, 2H), 1.46 (t, J = 5.9 Hz, 3H); LRMS (ESI) m / z calcd for C 9 H 9 Cl 2 NO [M + H] +: 219, Found 219.

(6-2) 3,4- Of dichlorobenzimidamide  Produce

Substantially the same process as Preparation Example (1-2), except that ethyl 3,4-dichlorobenzimidate obtained in (6-1) of Example 4 was used instead of ethyl 2-naphthylimidadate. Was carried out to prepare 3,4-dichlorobenzimidamide.

a white solid (70%); ¹ H NMR (400 MHz, DMSO) δ 9.19 (s, 4H), 8.18 (s, 1H), 7.94 (d, 1H), 7.85 (d, 1H); LRMS (ESI) m / z calcd for C 7 H 7 Cl 3 N 2 [M + H] +: 226, Found 226.

(6-3) (2- (3,4- Dichlorophenyl Preparation of) -1H-imidazol-5-yl) methanol

Substantially the same process as Preparation Example (1-3), except that 3,4-dichlorobenzimidamide obtained in Example 6 (6-2) was used instead of 2-naphthylimideamide. To give (2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) methanol.

a brown solid (58%); ¹ H NMR (400 MHz, DMSO) δ 12.57 (s, 1H), 8.15 (dd, 1H), 7.90 (d, J = 1.9 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.03 ( d, J = 90.6 Hz, 1H), 5.07 (d, J = 103.1 Hz, 1H), 4.43 (d, J = 19.6 Hz, 2H); LRMS (ESI) m / z calcd for C 10 H 8 Cl 2 N 2 O [M + H] +: 244, Found 244.

(6-4) 2- (2- (3,4- Dichlorophenyl ) -1H-imidazol-5-yl) Acetonitrile  Produce

(2- (3,4-dichlorophenyl) -1H- obtained in (6-3) of Example 4 instead of (2- (naphthalen-2-yl) -1H-imidazol-5-yl) methanol Except for using imidazol-5-yl) methanol, substantially the same process as Preparation Example (1-4) was carried out to give 2- (2- (3,4-dichlorophenyl) -1H-imidazole -5-day) acetonitrile was obtained.

a yellow solid (75%); ¹ H NMR (400 MHz, DMSO) δ 12.78 (s, 1H), 8.13 (d, J = 2.0 Hz, 1H), 7.89 (dd, J = 8.5, 2.1 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.28 (s, 1H), 3.92 (s, 2H); LRMS (ESI) m / z calcd for C 11 H 7 Cl 2 N 3 [M + H] +: 253, Found 253.

(6-5) 2- (2- (3,4- Dichlorophenyl ) -1- (2- ( Methylthio Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile

2- (2- (3,4-di) obtained in (6-4) of Example 4 instead of 2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile Except for using chlorophenyl) -1H-imidazol-5-yl) acetonitrile, the procedure was substantially the same as in Production Example (1-5), to give 2- (2- (3,4-di Chlorophenyl) -1- (2- (methylthio) pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile was obtained.

a yellow solid (35%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.42 (d, J = 5.4 Hz, 1H), 7.61 (s, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.40 (d, J = 8.3 Hz , 1H), 7.15 (dd, J = 8.3, 2.0 Hz, 1H), 6.53 (d, J = 5.4 Hz, 1H), 3.74 (d, J = 0.8 Hz, 2H), 2.37 (s, 3H); LRMS (ESI) m / z calcd for C 16 H 11 Cl 2 N 5 S [M + H] +: 377, Found 377.

(6-6) 2- (2- (3,4- Dichlorophenyl ) -1- (2- ( Methylsulfonyl Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile

Instead of 2- (1- (2- (methylthio) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile, 2- (2- (3,4-dichlorophenyl) -1- (2- (methylthio) pyrimidin-4-yl) -1H-imidazol-5-yl) acetonite obtained in 6-5) A 2- (2- (3,4-dichlorophenyl) -1- (2- (methylsulfonyl) pyri) was carried out in substantially the same manner as in Production Example (1-6), except that reel was used. Midin-4-yl) -1H-imidazol-5-yl) acetonitrile.

a white solid (83%); ¹ H NMR (400 MHz, DMSO) δ 9.13 (d, J = 5.6 Hz, 1H), 8.03 (s, 1H), 7.84 (d, J = 2.0 Hz, 1H), 7.80 (d, J = 5.6 Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.47 (dd, J = 8.4, 2.1 Hz, 1H), 4.07 (d, J = 0.8 Hz, 2H), 3.14 (s, 3H); LRMS (ESI) m / z calcd for C 16 H 11 Cl 2 N 5 O 2 S [M + H] +: 409, Found 409.

(6-7) tert -Butyl (S) -3- (4- (5- ( Cyanomethyl ) -2- (3,4- Dichlorophenyl ) -1H-imidazol-1-yl) pyrimidin-2-ylamino) piperidine-1-carboxylate

Example 4 instead of 2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile 2- (2- (3,4-dichlorophenyl) -1- (2- (methylsulfonyl) pyrimidin-4-yl) -1H-imidazol-5-yl) aceto obtained in 6-6) Except for using nitrile, the procedure was substantially the same as in Preparation Example (1-7) to give tert-butyl (S) -3- (4- (5- (cyanomethyl) -2- (3 , 4-dichlorophenyl) -1H-imidazol-1-yl) pyrimidin-2-ylamino) piperidine-1-carboxylate was obtained.

a yellow solid (83%); ¹ H NMR (400 MHz, MeOD) δ 8.33 (d, J = 4.6 Hz, 1H), 7.71 (dd, J = 5.4, 3.2 Hz, 1H), 7.66 (s, 1H), 7.56 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 6.62 (d, 1H), 3.90 (s, 2H), 3.73 (s, 1H), 3.10-2.82 (m, 2H), 2.65 (s , 1H), 1.76-1.66 (m, 2H), 1.28 (s, 9H), 0.92-0.82 (m, J = 10.6, 5.9 Hz, 4H); LRMS (ESI) m / z calcd for C 25 H 27 Cl 2 N 4 O 2 [M + H] +: 528, Found 528.

(6-8) (S) -2- (2- (3,4- Dichlorophenyl ) -1- (2- (piperidine-3- Monoamino Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile

tert-butyl (S) -3- (4- (5- (cyanomethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-ylamino) piperi Tert-butyl (S) -3- (4- (5- (cyanomethyl) -2- (3,4-dichloro) obtained in Example 6 (6-7) instead of din-1-carboxylate Except for using phenyl) -1H-imidazol-1-yl) pyrimidin-2-ylamino) piperidine-1-carboxylate, the procedure was substantially the same as in Preparation Example (1-8). , (S) -2- (2- (3,4-dichlorophenyl) -1- (2- (piperidin-3-ylamino) pyrimidin-4-yl) -1H-imidazole-5- (1) Acetonitrile was obtained.

a white solid (47%); ¹ H NMR (400 MHz, MeOD) δ 8.45 (d, J = 5.5 Hz, 1H), 8.10 (s, 1H), 7.83 (d, J = 1.5 Hz, 1H), 7.73 (d, J = 8.3 Hz, 1H), 7.50 (dd, J = 8.6 Hz, 1H), 6.66 (d, 1H), 4.13 (s, 2H), 3.95 (s, 1H), 3.81-3.62 (m, 1H), 3.61-3.56 (m , 1H), 3.02-2.86 (m, 3H), 2.03 (s, 1H), 1.89-1.73 (m, 2H), 1.71-1.55 (m, J = 37.0 Hz, 2H); LRMS (ESI) m / z calcd for C 20 H 19 Cl 2 N 7 [M + H] +: 429, Found 429.

(6-9) (S) -2- (1- (2- (1- ( Cyclopropanecarbonyl Piperidine-3- Monoamino Preparation of Pyrimidin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetonitrile

(S) -2- (2- (naphthalen-2-yl) -1- (2- (piperidin-3-ylamino) pyrimidin-4-yl) -1H-imidazol-5-yl) aceto (S) -2- (2- (3,4-dichlorophenyl) -1- (2- (piperidin-3-ylamino) obtained in (6-8) of Example 4 instead of nitrile. Except for using pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile, the same procedure as in Production Example (1-9) was carried out to provide (S) -2- ( 1- (2- (1- (cyclopropanecarbonyl) piperidin-3-ylamino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazole-5- (1) Acetonitrile was obtained.

a white solid (32%); ¹ H NMR (400 MHz, MeOD) δ 8.33 (d, 1H), 7.73 (d, J = 24.2 Hz, 1H), 7.65 (s, 1H), 7.56 (dd, J = 8.2, 5.3 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 6.68 (d, 1H), 4.28 (s, 1H), 3.90 (d, J = 0.8 Hz, 2H), 2.68-2.51 (m, 1H), 2.06-1.97 (m, 2H), 1.87-1.73 (m, 2H), 1.59-1.47 (m, 2H), 1.31-1.25 (m, 2H), 0.94-0.76 (m, 4H), 0.68-0.58 (m, 1H) ; LRMS (ESI) m / z calcd for C 24 H 23 Cl 2 N 7 O [M + H] +: 497, Found 497.

(6-10) (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl )) Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetamide

(S) -2- (1- (2- (1- (cyclopropanecarbonyl) piperidin-3-ylamino) pyrimidin-4-yl) obtained in (6-9) of Example 4)- 2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetonitrile (0.37 g, 0.74 mmol) was dissolved in DMSO (14 ml) and then K ₂ CO ₃ (0.175 g, 1.27 mmol) and 30% H ₂ O ₂ solution (0.221 ml, 2.23 mmol) were added and stirred at room temperature for 24 hours. After the reaction was completed, water was added, extracted with EA, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (S) -2- (1- (2-((1- (cyclopropanecarbonyl)). Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetamide was obtained.

¹ H NMR (400 MHz, CD ₃ OD) δ 8.33 (d, J = 13.6 Hz, 1H), 7.70-7.50 (m, 3H), 7.32 (d, J = 7.3 Hz, 1H), 6.65 (s, 1H ), 4.22 (s, 1H), 4.14-3.92 (m, 2H), 3.58 (s, 2H), 3.15 (d, J = 59.8 Hz, 3H), 2.66 (s, 1H), 2.11-1.36 (m, 7H), 0.88 (d, J = 41.4 Hz, 3H), 0.65 (d, J = 41.3 Hz, 2H); LRMS (ESI) m / z calcd for C 24 H 25 Cl 2 N 7 O 2 [M + H] +: 514, Found 514.

Example 5: Preparation of Compound 18h (Formula 18h)

(S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl obtained in (4-8) of Example 2 above ) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) -2-methylpropannitrile (1.0 g, 1.98 mmol) was dissolved in DMSO (50 ml) and then K ₂ CO ₃ at 0 ° C. (0.23 g, 1.68 mmol) and 30% H ₂ O ₂ solution (0.6 ml, 17.8 mmol) were added and stirred at room temperature for 24 hours. After the reaction was completed, water was added, extracted with EA, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography to obtain a compound.

a white solid (58%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.08 (s, 1H), 8.02 (s, 1H), 7.88-7.79 (m, 3H), 7.56-7.48 (m, 3H), 7.46 (d, J = 8.3 Hz, 1H), 6.09 (s, 1H), 5.44 (d, J = 39.3 Hz, 2H), 4.15 (s, 2H), 3.74 (s, 2H), 3.38 (s, 2H), 1.69 (s, 2H ), 1.66 (s, 6H), 0.79 (dd, J = 107.7, 67.8 Hz, 6H).

Example 6: Preparation of Compound 23a (Formula 23a)

(S) -2- (1- (2- (1- (cyclopropanecarbonyl) piperidin-3-ylamino) pyrimidin-4-yl) obtained in (6-9) of Example 4)- To 2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetonitrile (40 mg, 0.08 mmol) was added trimethylchlorosilane (0.2 ml, 1.6 mmol) at 0 ° C., followed by H ₂ O (0.8 ml, 44 mmol) was added slowly. It was stirred at rt for 20 h. Saturated NaHCO ₃ was added to the reaction mixture at 0 ° C., ethyl acetate was added and the aqueous layer was separated. The aqueous layer was neutralized with 1M HCl, extracted with ethyl acetate, and the organic layer was washed with water and brine. The water was then removed with anhydrous magnesium sulfate (MgSO ₄ ) and the solvent was evaporated to give (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) Pyrimidin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetic acid was obtained.

a white solid (58%); ¹ H NMR (400 MHz, MeOD) δ 8.33 (d, J = 13.6 Hz, 1H), 7.59 (m, 3H), 7.32 (d, J = 7.3 Hz, 1H), 6.65 (s, 1H), 4.22 ( s, 1H), 4.13-3.91 (m, 2H), 3.58 (s, 2H), 3.15 (m, 3H), 2.66 (s, 1H), 2.07-1.35 (m, 7H), 0.88 (d, J = 41.4 Hz, 3H), 0.65 (d, J = 41.3 Hz, 2H); LRMS (ESI) m / z calcd for C 24 H 24 Cl 2 N 6 O 3 [M + H] +: 515, Found 515.

Example 7: Preparation of Compound 23b (Formula 23b)

(9-1) 2- (2- (3,4- Dichlorophenyl Preparation of 1) -1H-imidazol-5-yl) acetic acid

To 2- (2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetonitrile (8.0 g, 31.8 mmol) was slowly added 6N HCl (160 ml) at 0 ° C. and 150 ° C. Stir at 12 h. After cooling to room temperature, the solid product was stirred until separation. The solid product was filtered and washed with H ₂ O to afford 2- (2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetic acid.

a white solid (97%); ¹ H NMR (400 MHz, DMSO) δ 8.37 (s, 1H), 8.05 (s, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.61 (s, 1H), 3.83 (s, 2H).

(9-2) ethyl 2- (2- (3,4-) Dichlorophenyl Preparation of) -1H-imidazol-5-yl) acetate

2- (2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetic acid (6.6 g, 24.3 mmol) obtained in (9-1) of Example 7 was added to ethanol (200 ml). After melting, conc. H ₂ SO ₄ (1 ml) was added slowly and refluxed for 12 h. After concentration, water was added, extraction was performed with EA, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography, ethyl 2- (2- (3,4-dichlorophenyl) -1H-imidazole-5 -Yl) acetate was obtained.

¹ H NMR (400 MHz, CDCl ₃ ) δ 7.86 (d, J = 2.1 Hz, 1H), 7.60 (dd, J = 8.4, 2.1 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.08 (d, J = 0.5 Hz, 1H), 4.52 (d, J = 0.5 Hz, 2H), 3.59 (q, J = 7.0 Hz, 2H), 1.22 (dd, J = 7.9, 6.2 Hz, 3H).

(9-3) ethyl 2- (2- (3,4-) Dichlorophenyl ) -1- (2- ( Methylthio Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) acetate

Ethyl 2- (2- (3,4-) obtained in (9-2) of Example 7 above instead of 2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile Except for using dichlorophenyl) -1H-imidazol-5-yl) acetate, substantially the same process as in Production Example (1-5) was carried out to obtain ethyl 2- (2- (3,4-di Chlorophenyl) -1- (2- (methylthio) pyrimidin-4-yl) -1H-imidazol-5-yl) acetate was obtained.

a white solid (78%); ¹ H NMR (400 MHz, DMSO) δ 8.68 (d, J = 5.49 Hz, 1H), 7.79 (s, 1H), 7.72 (m, 1H), 7.64 (d, J = 8.43 Hz, 1H), 7.35 ( m, 1H), 7.20 (d, J = 5.31 Hz, 1H), 4.10 (q, J = 7.1 Hz, 2H), 3.67 (s, 2H), 2.15 (s, 3H), 1.20 (t, 6.6 Hz, 3H).

(9-4) ethyl 2- (2- (3,4-) Dichlorophenyl ) -1- (2- ( Methylsulfonyl Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) acetate

Example 7 above instead of 2- (1- (2- (methylthio) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile Ethyl 2- (2- (3,4-dichlorophenyl) -1- (2- (methylthio) pyrimidin-4-yl) -1H-imidazol-5-yl) acetate obtained in 9-3) A 2-ethyl 2- (2- (3,4-dichlorophenyl) -1- (2- (methylsulfonyl) pyri) was carried out in substantially the same manner as in Production Example (1-6) except that it was used. Midin-4-yl) -1H-imidazol-5-yl) acetate was obtained.

White solid (40%), ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.81 (d, J = 5.6 Hz, 1H), 7.76 (t, J = 0.9 Hz, 1H), 7.66 (d, J = 2.1 Hz , 1H), 7.49 (d, J = 8.3 Hz, 1H), 7.26-7.22 (m, 1H), 7.12 (d, J = 5.6 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 3.73 (d, J = 0.9 Hz, 2H), 3.24 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H).

(9-5) tert -Butyl (S) -3-((4- (2- (3,4-) Dichlorophenyl ) -5- (2- Ethoxy -2- Oxoethyl Preparation of) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate

Example 7, instead of 2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile 2-ethyl 2- (2- (3,4-dichlorophenyl) -1- (2- (methylsulfonyl) pyrimidin-4-yl) -1H-imidazole-5 obtained in (9-4) Except for using -yl) acetate, tert-butyl (S) -3-((4- (2- (3,4-di) was subjected to substantially the same process as Preparation Example (1-7). Chlorophenyl) -5- (2-ethoxy-2-oxoethyl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate was obtained.

¹ H NMR (400 MHz, CDCl ₃ ) δ 8.22 (d, J = 5.3 Hz, 1H), 7.65 (s, 1H), 7.55 (s, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.24 (dd, J = 8.3, 2.0 Hz, 1H), 6.22 (s, 1H), 5.35 (s, 1H), 4.21 (q, J = 7.1 Hz, 2H), 3.71 (d, J = 0.5 Hz, 2H) , 3.55 (s, 1H), 3.50-3.02 (m, 4H), 1.73 (s, 2H), 1.51 (s, 2H), 1.42 (s, 9H), 1.29 (t, J = 7.1 Hz, 3H).

(9-6) ethyl (S) -2- (2- (3,4-) Dichlorophenyl ) -1- (2- (piperidine-3- Monoamino Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) acetate

tert-butyl (S) -3- (4- (5- (cyanomethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-ylamino) piperi Tert-butyl (S) -3-((4- (2- (3,4-dichlorophenyl) -5- () obtained in (9-5) of Example 7 above instead of din-1-carboxylate. Preparation Example (1-8), except that 2-oxy-2-oxoethyl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate was used Ethyl (S) -2- (2- (3,4-dichlorophenyl) -1- (2- (piperidin-3-ylamino) pyrimidin-4-yl ) -1H-imidazol-5-yl) acetate was obtained.

(9-7) ethyl (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl )) Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetate

(S) -2- (2- (naphthalen-2-yl) -1- (2- (piperidin-3-ylamino) pyrimidin-4-yl) -1H-imidazol-5-yl) aceto Ethyl (S) -2- (2- (3,4-dichlorophenyl) -1- (2- (piperidin-3-ylamino) obtained in Example 9 (9-6) instead of nitrile. Except for using pyrimidin-4-yl) -1H-imidazol-5-yl) acetate, the process was carried out substantially the same as in Preparation Example (1-9) to give ethyl (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazole -5-day) acetate was obtained.

¹ H NMR (400 MHz, CDCl ₃ ) δ 8.23 (s, 1H), 7.63 (s, 1H), 7.52 (s, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.26-7.18 (m, 1H), 6.26 (s, 1H), 5.48 (s, 1H), 4.21 (q, J = 7.1 Hz, 2H), 3.97 (s, 1H), 3.75 (s, 1H), 3.72 (s, 2H), 3.57 (s, 2H), 3.39 (s, 2H), 1.77 (s, 2H), 1.59 (s, 2H), 1.31 (d, J = 7.1 Hz, 3H), 1.01 (s, 1H), 0.85-0.83 (m, 1 H), 0.76 (s, 1 H), 0.59 (s, 1 H); LRMS (ESI) m / z calcd for [M + H] +: 543, Found 543.

Example 8: Preparation of Compound 23c (Formula 23c)

(10-1) 2- (2- (3,4- Dichlorophenyl ) -1- (2- ( Methylthio Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) -2-fluoroacetonitrile

2- (2- (3,4-dichlorophenyl) -1- (2- (methylthio) pyrimidin-4-yl) -1H-imidazole- obtained in (6-5) of Example 4 above 5-day) Acetonitrile (0.75 g, 2 mmol) and 1.7 M t-BuLi (1.17 ml, 2 mmol) were mixed with THF (20 ml) and stirred at -78 ° C for 15 minutes. NFSI (0.75 mg, 2.4 mmol) was then added and stirred at 0 ° C. for 2 hours. After confirming the reaction termination on TLC, the reaction mixture was extracted with ethyl acetate (EtOAc). The organic layer was washed with water and brine. Anhydrous magnesium sulfate was dried over it, the solvent was concentrated, and column chromatography was purified by using EA: HEX (1: 2) mobile phase to obtain 2- (2- (3,4-dichlorophenyl) -1- (2- (Methylthio) pyrimidin-4-yl) -1H-imidazol-5-yl) -2-fluoroacetonitrile was obtained.

a yellow solid (4%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.52 (d, J = 5.3 Hz, 1H), 8.01 (d, J = 4.2 Hz, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.49 (d , J = 8.3 Hz, 1H), 7.24 (dd, J = 8.3, 2.1 Hz, 1H), 6.61 (d, J = 5.3 Hz, 1H), 6.22-6.10 (d, 1H), 2.48 (s, 3H) ; LRMS (ESI) m / z calcd for C 16 H 10 Cl 2 FN 5 S [M + H] +: 395, Found 395.

(10-2) tert -Butyl (S) -3- (4- (5- ( Cyanofluoromethyl ) -2- (3,4- Dichlorophenyl Preparation of) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate

2- (2- (3,4-dichlorophenyl) -1- (2- (methylthio) pyrimidin-4-yl) -1H-imidazole- obtained in (10-1) of Example 8 above 5-yl) -2-fluoroacetonitrile (0.04 g, 0.1 mmol) and potassium peroxomonosulfate mixed with methanol: water = 1: 1 (v: v) (0.5 ml) Was mixed at room temperature for 1 hour, and after the compound (6-6) disappeared completely in TLC, methanol was concentrated in vacuo. To the concentrated mixture was added water, diluted, stirred until the solid product was separated and filtered to give a solid product (0.042 g, 0.1 mmol). After dissolving in THF (1ml), tert-butyl 3-aminopiperidine-1-carboxylate (tert-butyl 3-aminopiperidine-1-carboxylate, 0.05g, 0.25mmol) was added and stirred at 60 ℃ for 5 hours. It was. After confirming the reaction termination, the reaction mixture was cooled to ambient temperature and concentrated in vacuo. Column chromatography was purified using a mobile phase of MC: MeOH (40: 1) to give tert-butyl (S) -3- (4- (5- (cyanofluoromethyl) -2- (3,4-di Chlorophenyl) -1H-imidazol-1-yl) pyrimidin-2-ylamino) piperidine-1-carboxylate was obtained.

a yellow solid (22%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.26 (s, 1H), 7.68 (s, 1H), 7.53 (dd, J = 5.6, 3.4 Hz, 1H), 7.48 (d, J = 8.3 Hz, 1H) , 7.28 (d, J = 7.8 Hz, 1H), 6.24 (s, 1H), 6.21-6.09 (d, 1H), 4.33-4.27 (m, 1H), 4.15-4.09 (m, 1H), 3.88 (s , 1H), 3.66 (d, J = 9.1 Hz, 1H), 3.45 (d, J = 35.7 Hz, 2H), 3.29 (d, J = 10.7 Hz, 2H), 3.01 (s, 1H), 1.46 (s , 9H); LRMS (ESI) m / z calcd for C 25 H 26 Cl 2 FN 7 O 2 [M + H] +: 547, Found 547.

(10-3) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3, Preparation of 4-dichlorophenyl) -1H-imidazol-5-yl) -2-fluoroacetamide

Tert-butyl-3- (4- (5- (cyanofluoromethyl) -2- (3,4-dichlorophenyl) -1H-imidazole- obtained in (10-2) of Example 8) 1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate (0.012 g, 0.022 mmol) is dissolved in 0.25 ml of 1,4-dioxane and 1,4- Stir with 0.055 ml of 4M-HCl in dioxane at room temperature for 30 minutes. After confirming the completion of the reaction, the mixture was diluted with ether and stirred until it separated into a solid. The solid product was obtained by filtration and dissolved in 0.2 ml of DCM (CH ₂ Cl ₂ ). Thereafter, TEA (6 μl, 0.044 mmol) was mixed at 0 ° C., and stirred for 15 minutes, and cyclopropanecarbonyl chloride (1 μl, 0.11 mmol) was added thereto, followed by stirring at room temperature. After confirming the reaction, column chromatography was purified by using MC: MeOH (20: 1) mobile phase to obtain (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidine-3- Il) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) -2-fluoroacetamide was obtained.

a white solid (34%); ¹ H NMR (400 MHz, DMSO) δ 8.40 (s, 1H), 8.10-7.75 (m, 2H), 7.60 (d, J = 35.9 Hz, 3H), 7.33 (s, 1H), 6.71 (s, 1H ), 5.80 (d, J = 48.7 Hz, 1H), 3.98 (s, 2H), 2.93 (s, 2H), 1.95 (d, J = 13.3 Hz, 1H), 1.63 (s, 1H), 1.45 (s , 1H), 1.23 (s, 3H), 0.86 (dd, J = 8.1, 5.4 Hz, 1H), 0.70 (s, 2H), 0.55 (s, 1H); LRMS (ESI) m / z calcd for C 24 H 22 Cl 2 FN 7 O [M + H] +: 515, Found 515.

Example 9: Preparation of Compound 24

(11-1) 2,3- Dihydrobenzofuran -5- Carbonitrile  Produce

2,3-dihydrobenzofuran-5-carboaldehyde (1.4 g, 9.7 mmol) was dissolved in N-dimethylformamide (DMF) (50 ml), followed by anhydrous sodium sulfate (1.65 g, 11.7 mmol) and hydroxyamine-HCl ( 0.8 g, 11.7 mmol) were mixed together and stirred at 170 ° C. for 4 hours. After confirming the completion of the reaction, extraction was performed using EA (EtOAc). The organic layer was washed with water and brine. Drying with anhydrous sodium sulfate and concentration of the solvent gave 2,3-dihydrobenzofuran-5-carbonitrile.

a brown solid (98%); ¹ H NMR (400 MHz, DMSO) δ 7.70-7.67 (m, 1H), 7.61-7.56 (m, 1H), 6.95-6.91 (m, 1H), 4.64 (t, J = 8.8 Hz, 2H), 3.22 (d, J = 8.7 Hz, 2H); LRMS (ESI) m / z calcd for C 9 H 7 NO [M + H] +: 146, Found 146.

(11-2) ethyl 2,3- Dihydrobenzofuran -5- Carbomidate  Produce

2,3-dihydrobenzofuran-5-carbonitrile (4.8 g, 33 mmol) obtained in (11-1) of Example 9 was dissolved in ethanol (23 ml, 397 mmol), and then acetyl chloride (AcCl) at 0 ° C. , 19ml, 265mmol) was added slowly and stirred at room temperature for 24-48 hours. After 2,3-dihydrobenzofuran-5-carbonitrile disappeared completely in TLC, it was concentrated in vacuo, and the concentrated mixture was diluted with ether and stirred until the solid product separated. The solid product was filtered and washed sequentially with ether and hexane solvents to give ethyl 2,3-dihydrobenzofuran-5-carbodiimidate

a yellow solid (94%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 12.07 (s, 1H), 11.41 (s, 1H), 8.37 (s, 1H), 8.17 (d, J = 5.3 Hz, 1H), 6.87 (d, J = 5.7 Hz, 1H), 4.88 (s, 2H), 4.69 (s, 2H), 3.31 (s, 2H), 1.59 (s, 3H); LRMS (ESI) m / z calcd for C 11 H 13 NO 2 [M + H] +: 192, Found 192.

(11-3) 2,3- Dihydrobenzofuran -5- Of carboxyimidamide  Produce

Ethyl 2,3-dihydrobenzofuran-5-carbodimidate (6.1 g, 32 mmol) obtained in Example 11 (11-2) and methanol (32 ml) dissolved in 7N ammonia were ethanol (32 ml). ), And the mixture was stirred at rt for 12 h. After ethyl 2,3-dihydrobenzofuran-5-carbodiimate disappeared completely in TLC, it was concentrated in vacuo, and the concentrated mixture was diluted with ether and stirred until the solid product separated. The solid product was filtered and washed sequentially with ether and hexane solvents to give 2,3-dihydrobenzofuran-5-carboxyimidamide, a crystallized compound.

a brown solid (85%); ¹ H NMR (400 MHz, DMSO) δ 9.22 (s, 1H), 9.07 (s, 1H), 7.79 (s, 1H), 7.69 (dd, J = 8.5, 2.1 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 4.67 (t, J = 8.8 Hz, 2H), 3.25 (t, J = 8.8 Hz, 2H); LRMS (ESI) m / z calcd for C 9 H 10 N 2 O [M + H] +: 163, Found 163.

(11-4) (2- (2,3- Dihydrobenzofuran Preparation of -5-yl) -1H-imidazol-5-yl) methanol

2,3-dihydrobenzofuran-5-carboxyimidamide (5 g, 31 mmol) and 1,3-dihydroxyacetone dimer obtained in Example 11 (11-3), 7.2 g, 40 mmol), 28% NH ₄ OH (150 ml), NH ₄ Cl (8.2 g, 0.154 mol) were stirred at 80 ° C. for 2 hours. After 2,3-dihydrobenzofuran-5-carboxyimidamide disappeared completely in TLC, the reaction mixture was cooled to room temperature and methylene chloride (CH ₂ Cl ₂ ) was added to separate the layers. The solid product formed in the organic layer was filtered, washed with methylene chloride (CH ₂ Cl ₂ ) and crystallized to give (2- (2,3-dihydrobenzofuran-5-yl) -1H-imidazol-5-yl Methanol was obtained.

a brown solid (56%); ¹ H NMR (400 MHz, DMSO) δ 7.82 (d, J = 1.0 Hz, 1H), 7.70 (dd, J = 8.4, 1.7 Hz, 1H), 7.00 (s, 1H), 6.83 (d, J = 8.3 Hz, 1H), 5.13 (s, 1H), 4.57 (t, J = 8.7 Hz, 2H), 4.42 (s, 2H), 3.22 (t, J = 8.7 Hz, 2H); LRMS (ESI) m / z calcd for C 12 H 12 N 2 O 2 [M + H] +: 217, Found 217.

(11-5) 2- (2- (2,3- Dihydrobenzofuran -5-yl) -1H-imidazol-5-yl) Acetonitrile  Produce

To (2- (2,3-dihydrobenzofuran-5-yl) -1H-imidazol-5-yl) methanol (0.69 g, 3.2 mmol) obtained in (11-5) of Example 9, DCM ( 12.5 ml) and thionyl chloride (0.46 ml, 6.4 mol) were mixed and stirred at room temperature until (2- (naphthalen-2-yl) -1H-imidazol-5-yl) methanol disappeared from TLC. After the reaction was completed, the solvent was removed in vacuo, and dimethyl sulfoxide (16 ml) was added to the compound and sodium cyanide (0.78 g, 16 mmol) obtained therefrom and stirred at room temperature for 24 hours. It was. After confirming the completion of the reaction, the reaction mixture was extracted with ethyl acetate (EtOAc), and then the organic layer was washed with water and brine, after which water was removed with anhydrous magnesium sulfate (MgSO ₄ ) and the solvent was evaporated. Separation and purification by column chromatography (EA: HEX = 1: 1) yielded 2- (2- (2,3-dihydrobenzofuran-5-yl) -1H-imidazol-5-yl) acetonitrile. Obtained.

a brown solid (35%); ¹ H NMR (400 MHz, DMSO) δ 12.25 (s, 1H), 7.74 (d, J = 1.3 Hz, 1H), 7.61 (dd, J = 8.3, 1.9 Hz, 1H), 7.04 (s, 1H), 6.78 (d, J = 8.3 Hz, 1H), 4.52 (t, J = 8.7 Hz, 2H), 3.82 (s, 2H), 3.18 (t, J = 8.7 Hz, 2H); LRMS (ESI) m / z calcd for C 13 H 11 N 3 O [M + H] +: 226, Found 226.

(11-6) 2- (2- (2,3- Dihydrobenzofuran -5-day) -1- (2- ( Methylthio Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile

2- (2- (2,3-dihydrobenzofuran-5-yl) -1H-imidazol-5-yl) acetonitrile (0.25 g, 1.1 mmol) obtained in (11-5) of Example 9; ) Was dissolved in anhydrous DMF (5.5ml, 0.2M), and 0.5M KHMDS in toluene (2.2ml, 1.1mmol) was added slowly at 0 ° C. After stirring for 30 minutes at 0 ° C, 4-chloro-2- (methylthio) pyrimidine (4-chloro-2- (methylthio) pyrimidine, 0.13ml, 1.1mmol) was added slowly and stirred at 80 ° C for 24 hours. . After cooling to room temperature, water was added, the organic layer was extracted with ethyl acetate (EtOAc), and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (EA: HEX = 1: 1), followed by purification of 2- (2- (2,3-dihydrobenzo). Furan-5-yl) -1- (2- (methylthio) pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile was obtained.

a brown solid (18%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.40 (d, J = 5.4 Hz, 1H), 7.72 (s, 1H), 7.37 (s, 1H), 7.13 (s, 1H), 6.78 (d, J = 8.3 Hz, 1H), 6.54 (d, J = 5.4 Hz, 1H), 4.66 (d, J = 8.8 Hz, 2H), 3.85 (s, 2H), 3.24 (d, J = 8.7 Hz, 2H), 2.54 (s, 3H); LRMS (ESI) m / z calcd for C 18 H 15 N 5 OS [M + H] +: 350, Found 350.

(11-7) tert -Butyl (S) -3- (4- (5- ( Cyanomethyl ) -2- (2,3- Dihydrobenzofuran Preparation of -5-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate

(S) -2- (2- (2,3-dihydrobenzofuran-5-yl) -1- (2- (methylthio) pyrimidine-4 obtained in (11-6) of Example 9; -Yl) -1H-imidazol-5-yl) acetonitrile (0.077g, 0.22mmol) and potassium peroxomonosulfate (potassium peroxomonosulfate) mixed with methanol: water = 1: 1 (v: v) (1.1 ml), stirred for 1 hour at room temperature, and after Compound (6-6) disappeared completely in TLC, the methanol was concentrated in vacuo. To the concentrated mixture was added water, diluted, stirred until the solid product was separated and filtered to give a solid product (0.061 g, 0.16 mmol). After dissolving in THF (1ml), tert-butyl (S) -3-aminopiperidine-1-carboxylate (tert-butyl 3-aminopiperidine-1-carboxylate, 0.065g, 0.32mmol) was added to 60 ℃ Stir for 5 hours. After confirming the reaction termination, the reaction mixture was cooled to ambient temperature and concentrated in vacuo. Column chromatography was purified using a mobile phase of MC: MeOH (40: 1) to give tert-butyl (S) -3- (4- (5- (cyanomethyl) -2- (2,3-dihydrobenzo) Furan-5-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate was obtained.

a yellow solid (48%); LRMS (ESI) m / z calcd for C 27 H 31 N 7 O 3 [M + H] +: 502, Found 502.

(11-8) (S) -2- (1- (2- (1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (2,3 Preparation of dihydrobenzofuran-5-yl) -1H-imidazol-5-yl) acetonitrile

Tert-butyl (S) -3- (4- (5- (cyanomethyl) -2- (2,3-dihydrobenzofuran-5-yl) obtained in (11-7) of Example 9) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate (0.053 g, 0.105 mmol) in 1,4-dioxane (1,4-dioxane) (1.1 ml ) And stirred with 0.53 ml of 4M-HCl in 1,4-dioxane at room temperature for 30 minutes. After confirming the completion of the reaction, the mixture was diluted with ether and stirred until it separated into a solid. Filtration then gave a solid product (0.042 g, 0.105 mmol). Dissolved in 1.1 ml of DCM. Thereafter, TEA (30 μl, 0.21 mmol) was mixed and mixed at 0 ° C. for 15 minutes, and cyclopropanecarbonyl chloride (9.5 μl, 0.105 mmol) was added thereto, followed by stirring at room temperature. After confirming the reaction, column chromatography was purified by using MC: MeOH (20: 1) mobile phase to obtain (S) -2- (1- (2- (1- (cyclopropanecarbonyl) piperidin-3-yl ) Amino) pyrimidin-4-yl) -2- (2,3-dihydrobenzofuran-5-yl) -1H-imidazol-5-yl) acetonitrile.

a white solid (20%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.14 (s, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.33 (s, 1H), 7.11 (d, J = 10.8 Hz, 1H), 6.74 (d, J = 8.1 Hz, 1H), 6.09 (s, 1H), 4.61 (t, J = 8.7 Hz, 2H), 3.99-3.95 (m, 2H), 3.85 (d, J = 9.6 Hz, 2H) , 3.76 (s, J = 0.9 Hz, 2H), 3.21 (t, J = 8.8 Hz, 2H), 1.77-1.75 (m, 2H), 1.59 (d, J = 3.4 Hz, 2H), 1.25 (s, 2H), 1.01-0.99 (m, 2H), 0.87 (d, J = 3.6 Hz, 1H), 0.86 (d, J = 2.9 Hz, 1H); LRMS (ESI) m / z calcd for C 26 H 27 N 7 O 2 [M + H] +: 470, Found 470.

Example 10 Preparation of Compound 25

(12-1) 2- (2- (3,4- Dichlorophenyl ) -1- (2- ( Methylthio Preparation of Pyrimidin-4-yl) -1H- (imidazol-5-yl) -propanenitrile

2- (2- (3,4-dichlorophenyl) -1- (2- (methylthio) pyrimidin-4-yl) -1H- (imidazole-) obtained in (6-5) of Example 4 above. 5-day) -acetonitrile (125 mg, 0.332 mmol) was dissolved in anhydrous THF (0.664 ml, 0.5 M) and NaH 60% dispersion in mineral oil (15.9 mg, 0.398 mmol) was added at 0 ° C. for 30 minutes. After stirring at 0 ° C., MeI (24.8 μl, 0.398 mmol) was slowly added to the mixture, and stirred for 1 hour at 0 ° C. After the reaction was completed, water was added and the organic layer was extracted with ethyl acetate (EtOAc). The organic layer was washed with water and brine, after which water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, separated and purified by column chromatography (EA: HEX = 1: 3), and purified. -(2- (3,4-Dichlorophenyl) -1- (2- (methylthio) pyrimidin-4-yl) -1H- (imidazol-5-yl) -propannitrile was obtained.

a yellow oil (18%); ¹ H NMR (400 MHz, DMSO) δ 8.73 (d, J = 5.4 Hz, 1H), 7.94 (d, J = 0.8 Hz, 1H), 7.76 (d, J = 2.0 Hz, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.39 (dd, J = 8.4, 2.1 Hz, 1H), 7.27 (d, J = 5.4 Hz, 1H), 4.37-4.30 (m, 1H), 2.16 (s, 3H), 1.62 (d, J = 7.2 Hz, 3H); LRMS (ESI) m / z calcd for C 20 H 15 N 5 S [M + H] +: 391, Found 391.

(12-2) tert -Butyl 3-((4- (5- (1- Cyanoethyl ) -2- (3,4- Dichlorophenyl Preparation of) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate

2- (2- (3,4-dichlorophenyl) -1- (2- (methylthio) pyrimidin-4-yl) -1H- (imidazole-) obtained in (12-2) of Example 10 above. 5-yl) -propanenitrile (74.2 mg, 0.190 mmol) and methanol (2.51 ml) were premixed, and potassium peroxomonosulfate (627 mg, 1.02 mmol) per water (2.51 ml, 0.25 g oxone) 1 ml) and added slowly after mixing, the mixture was stirred for 1 hour at room temperature 2- (2- (3,4-dichlorophenyl) -1- (2- (methylthio) pyrimidine-4- After the 1) -1H- (imidazol-5-yl) -propanenitrile disappeared completely in TLC, it was concentrated in vacuo The mixture was extracted with water and ethyl acetate (EtOAc), and the organic layer was washed with water and brine. washed with brine, followed by removal of water with anhydrous magnesium sulfate (MgSO ₄ ) and evaporation of the solvent to give 2- (2- (3,4-dichlorophenyl) -1- (2- (methylsulfonyl) Pyrimidin-4-yl) -1H- (imidazol-5-yl) -propane Yttryl was obtained.

(12-3) tert -Butyl (S) -3-((4- (5- (1- Cyanoethyl ) -2- (3,4- Dichlorophenyl Preparation of) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate

2- (2- (3,4-dichlorophenyl) -1- (2- (methylsulfonyl) pyrimidin-4-yl) -1H- (imidazole obtained in (12-2) of Example 10 above -5-yl) -propanenitrile (59.7 mg, 0.141 mmol) with tert-butyl (S) -3-aminopiperidine-1-carboxylate, 55.6 μl, 0.283 mmol) was stirred in THF (1.41 ml, 0.1 M) for 12 h at 60 ° C. 2- (2- (3,4-dichlorophenyl) -1- (2- (methylsulfonyl) pyrimidine- After 4-yl) -1H- (imidazol-5-yl) -propannitrile disappeared completely, the reaction mixture was cooled to room temperature and concentrated in vacuo.The concentrated mixture was subjected to column chromatography (EA: Hex = 2). Purification by separation into tert-butyl (S) -3-((4- (5- (1-cyanoethyl) -2- (3,4-dichlorophenyl) -1H-imidazole-1) -Yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate was obtained.

a yellow oil (62%); ¹ H NMR (400 MHz, MeOD) δ 8.36 (d, J = 4.8 Hz, 1H), 7.76 (s, 1H), 7.69 (d, J = 1.7 Hz, 1H), 7.59 (d, J = 8.3 Hz, 1H), 7.34 (d, J = 8.1 Hz, 1H), 6.65 (s, 1H), 4.21 (q, J = 7.3 Hz, 1H), 3.80 (s, 4H), 2.96 (d, J = 24.8 Hz, 4H), 1.73 (d, J = 7.2 Hz, 3H), 1.42 (dd, J = 47.7, 4.2 Hz, 9H); LRMS (ESI) m / z calcd for C 29 H 31 N 7 O 2 [M + H] +: 543, Found 543.

(12-4) (S) -2- (2- (3,4- Dichlorophenyl ) -1- (2- (piperidine-3- Monoamino Preparation of Pyrimidin-4-yl) -1H-imidazol-5-yl) propanenitrile

Tert-butyl (S) -3-((4- (5- (1-cyanoethyl) -2- (3,4-dichlorophenyl) -1H- obtained in (12-3) of Example 10) Imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate (51.4 mg, 0.0948 mmol) is dissolved in 1,4-dioxane (0.948 ml, 0.1 M) and 4M-HCl After treatment with 1,4-dioxane (0.238 ml, 0.948 mmol), the reaction mixture was stirred at room temperature for 1 hour. After completion of the reaction, it was concentrated in vacuo. The concentrated mixture was diluted by adding ether, the solid product was separated and the solid product was filtered, washed sequentially with ether and hexane solvents and crystallized to give (S) -2- (2- (3,4-dichlorophenyl). ) -1- (2- (piperidin-3-ylamino) pyrimidin-4-yl) -1H-imidazol-5-yl) propannitrile was obtained.

(12-5) (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl Preparation of)) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) propanenitrile

(S) -2- (2- (3,4-dichlorophenyl) -1- (2- (piperidin-3-ylamino) pyrimidine-4 obtained in (12-4) of Example 10; -Yl) -1H-imidazol-5-yl) propanenitrile (41.9 mg, 0.0948 mmol) was dissolved in anhydrous THF (0.948 ml, 0.1 M) and (1- (cyclopropanecarbonyl) piperidine-3- I) carbamate (10.3 μl, 0.114 mmol) and TEA (26.4 μl, 0.19 mol) were added at 0 ° C. and stirred for 1 hour. After the reaction was completed, the mixture was concentrated in vacuo and the mixture was extracted with water and DCM, and then the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (EA: Hex = 3: 1) to obtain (S) -2- (1- (2- ( (1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) propanite Reels were obtained.

a yellow oil (43%); ¹ H NMR (400 MHz, MeOD) δ 8.42-8.31 (m, 1H), 7.82-7.66 (m, 2H), 7.59 (d, J = 8.6 Hz, 1H), 7.35 (d, J = 6.8 Hz, 1H ), 6.62 (s, 1H), 4.31 (s, 1H), 4.20 (q, J = 7.2 Hz, 1H), 4.04 (s, 1H), 3.23-2.59 (m, 3H), 1.91 (d, J = 52.2 Hz, 2H), 1.72 (d, J = 7.2 Hz, 3H), 1.53 (s, 2H), 0.98-0.59 (m, 5H); LRMS (ESI) m / z calcd for C 30 H 31 N 7 O [M + H] +: 511, Found 511.

Production Example  (13-1) 5-((( tert - Butyldimethylsilyl ) Oxy ) methyl Preparation of) -2- (naphthalen-2-yl) -1H-imidazole

(2- (naphthalen-2-yl) -1H-imidazol-5-yl) methanol (25 g, 11.15 mmol) obtained in Preparation Example (1-3) was dissolved in DMF (350 mL, 0.1 M), and then imidazole. (15.2 g, 22.31 mmol) and TBDMS-Cl (14.6 g, 13.39 mmol, 1.2 eq) were added thereto, followed by stirring at room temperature for 18 hours. Water was added and the organic layer was extracted with ethyl acetate (EtOAc), and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and the mixture was separated and purified by column chromatography (EA: Hexane = 1: 1) to obtain a compound. 5-(((tert-butyldimethylsilyl) oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazole (TBS stands for tert-Butyldimethylsilyl).

(63.6%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 9.69 (s, 1H), 8.25 (d, J = 1.2 Hz, 1H), 7.96 (d, J = 8.6 Hz, 1H), 7.91-7.80 (m, 3H) , 7.52-7.45 (m, 2H), 7.05 (s, 1H), 4.82 (s, 2H), 0.94 (s, 9H), 0.13 (s, 6H).

Production Example  (13-2) 4- (5-((( tert - Butyldimethylsilyl ) Oxy ) methyl Preparation of) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) -2- (methylthio) pyrimidine

5-(((tert-butyldimethylsilyl) oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazole (12 g, 35.48 mmol) obtained in Preparation Example (13-1) was anhydrous DMF. After dissolving in (180ml, 0.2M), 0.5M KHMDS in toluene (80ml, 39.03mmol) was added slowly at 0 ° C. After stirring for 30 minutes at 0 ° C, 4-chloro-2- (methylthio) pyrimidine (4-chloro-2- (methylthio) pyrimidine, 4.1ml, 35.48mmol) was added slowly and stirred at 100 ° C for 24 hours. . After cooling to room temperature, water was added, the organic layer was extracted with ethyl acetate (EtOAc), and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (EA: HEX = 1: 1) to give a compound 4- (5-(((tert-butyldi) Methylsilyl) oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) -2- (methylthio) pyrimidine was obtained.

(48.4%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.45 (d, J = 5.4 Hz, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.51 (t, J = 1.1 Hz, 1H), 7.43 (d , J = 8.3 Hz, 1H), 7.21 (dd, J = 8.3, 2.1 Hz, 1H), 6.60 (d, J = 5.4 Hz, 1H), 4.77 (d, J = 1.1 Hz, 2H), 2.38 (s , 3H), 0.95 (s, 9H), 0.14 (s, 6H).

Example 11 Preparation of Compound 18d

(16-1) Preparation of 2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetic acid

To 2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile (13.1 g, 56 mmol) obtained in Preparation Example (1-4), conc. HCl (200ml) and water (200ml) were added thereto, and the mixture was stirred at 240 ° C for 15 hours. After cooling to room temperature, the resulting solids were filtered and washed with water. The filtered solid was dried in a 70 ° C. oven for one day to afford 2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetic acid.

white solid (100%); ¹ H NMR (400 MHz, DMSO-d6) δ 8.83 (d, J = 1.5 Hz, 1H), 8.25 (dd, J = 8.7, 1.9 Hz, 1H), 8.16 (d, J = 8.9 Hz, 1H), 8.06-7.96 (m, 2H), 7.72-7.62 (m, 3H), 3.89 (d, J = 20.4 Hz, 2H).

(16-2) N, N - Dimethyl -2- (2-naphthalen-2-yl) -1H-imidazol-5-yl) Acetamide  Produce

2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetic acid (7.48 g, 29.6 mmol) was dissolved in N, N-dimethylformamide (DMF, 296 ml) and then dimethylamine Hydrochloride (2.46g), triethylamine (TEA, 8.26ml) and HATU (68g, 177.6mmol) were added thereto and stirred at room temperature under nitrogen for 4 hours. After confirming that 2- (2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetic acid disappeared in TLC, water was added and stirred, and the resulting solid was filtered and washed with water. The filtrate was extracted with EA and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography to obtain N, N-dimethyl-2- (2-naphthalen-2-yl) -1H-imide. Dazol-5-yl) acetamide was obtained.

(71.3%); ¹ H NMR (400 MHz, DMSO-D6) δ 8.47 (s, 1H), 8.06 (dt, J = 15.9, 5.2 Hz, 2H), 7.99-7.92 (m, 3H), 7.61-7.53 (m, 2H) , 7.20 (s, 1 H), 3.76 (s, 2 H), 2.90-2.85 (m, 6 H).

(16-3) N, N - Dimethyl -2- (1- (2- ( Methylthio Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetamide

It manufactured by the same process as the preparation example (1-5).

yellow foam (35%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.26 (d, J = 5.4 Hz, 1H), 8.01 (s, 1H), 7.86-7.77 (m, 3H), 7.71 (s, 1H), 7.55-7.46 ( m, 2H), 7.41 (dd, J = 8.5, 1.7 Hz, 1H), 6.49 (d, J = 5.4 Hz, 1H), 3.81 (s, 2H), 3.16 (s, 3H), 3.00 (s, 3H ), 2.32 (s, 3 H).

(16-4) N, N - Dimethyl -2- (1- (2- ( Methylsulfonyl Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetamide

It manufactured by the same process as the preparation example (1-6).

Brown foam (15%)

(16-5) (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl Preparation of Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) -N, N-dimethylacetamide

N, N-dimethyl-2- (1- (2- (methylsulfonyl) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetamide ( 0.225 g, 0.5 mmol) was dissolved in tetrahydrofuran (50 ml), followed by (S)-(3-aminopiperidin-1-yl) (cyclopropyl) methanone hydrogen chloride (0.21 g, 1 mmol) and triethyl Amine (0.7 ml, 5 mmol) was added and stirred at 80 ° C. for 12 h. The reaction mixture was concentrated in vacuo and then separated and purified by column chromatography (MC: MeOH = 1: 1) to give (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperi). Din-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) -N, N-dimethylacetamide was obtained.

Yellow solid (21%); ¹ H NMR (300 MHz, CD ₃ OD) δ 8.22 (s, 1H), 8.02 (s, 1H), 7.87 (d, J = 8.1 Hz, 3H), 7.64-7.51 (m, 3H), 7.42 (s , 1H), 6.67 (s, 1H), 3.81 (s, 2H), 3.21 (s, 3H), 3.01 (s, 3H), 2.78 (s, 2H), 2.01 (s, 1H), 1.96-1.32 ( m, 7H), 0.94-0.56 (m, 5H).

Example 12: Preparation of Compound 20c

(17-1) Preparation of 5-ethyl-2- (naphthalen-2-yl) -1H-imidazole

2-naphthymide amide (2.81 g, 16.6 mmol) obtained in Preparation Example (1-2) was dissolved in a solvent mixed with THF (100 ml) and water (25 ml), followed by potassium carbonate (6.4 g, 64.0 mmol). 1-bromo-2-butane (2.5 g, 16.6 mmol) was added thereto, followed by reflux and stirring for 15 hours. The reaction mixture was concentrated, poured into water, extracted with EA, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography to obtain 5-ethyl-2- (naphthalen-2-yl) -1H-imidazole.

(17-2) 4- (5-ethyl-2- (naphthalen-2-yl) -1H-imidazol-1-yl) -2- ( Methylthio Preparation of Pyrimidine

It manufactured by the same process as the preparation example (1-5).

(69%) ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.23 (d, J = 5.5 Hz, 1H), 8.04 (d, J = 1.4 Hz, 1H), 7.84-7.78 (m, 3H), 7.53- 7.46 (m, 2H), 7.45 (t, J = 1.1 Hz, 1H), 7.43 (dd, J = 8.5, 1.8 Hz, 1H), 6.45 (d, J = 5.5 Hz, 1H), 2.72 (qd, J = 7.5, 1.0 Hz, 2H), 2.38 (s, 3H), 1.33 (t, J = 7.5 Hz, 3H).

(17-3) 4- (5-ethyl-2- (naphthalen-2-yl) -1H-imidazol-1-yl) -2- ( Methylsulfonyl Preparation of Pyrimidine

It manufactured by the same process as the preparation example (1-6).

(64%) ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.59 (d, J = 5.6 Hz, 1H), 8.08-8.05 (m, 1H), 7.91-7.82 (m, 3H), 7.60 (t, J = 1.1 Hz, 1H), 7.56 (ddd, J = 7.1, 5.8, 3.4 Hz, 2H), 7.44 (dd, J = 8.5, 1.8 Hz, 1H), 6.97 (d, J = 5.6 Hz, 1H), 3.21 (s, 3H), 2.74 (qd, J = 7.5, 1.1 Hz, 2H), 1.34 (t, J = 7.5 Hz, 3H).

(17-4) (S)- Cyclopropyl (3-((4- (5-ethyl-2- Preparation of (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone

It manufactured by the same process as (16-5) of Example 11.

(27%) ¹ H NMR (400 MHz, CD ₃ OD) δ 8.22 (d, J = 33.4 Hz, 1H), 8.00 (s, 1H), 7.87 (dd, J = 11.2, 7.8 Hz, 3H), 7.53 (p, J = 7.6 Hz, 2H), 7.46 (s, 1H), 7.39 (d, J = 8.0 Hz, 1H), 6.56 (d, J = 54.3 Hz, 1H), 4.13 (s, 1H), 3.81 (s, 2H), 2.86 (s, 1H), 2.69 (q, J = 7.6 Hz, 3H), 2.54 (s, 1H), 1.75 (d, J = 98.2 Hz, 5H), 1.33 (t, J = 7.5 Hz, 3H), 0.98-0.55 (m, 5H).

Example 13: Preparation of Compound 20e

(18-1) 4- (5-((( tert - Butyldimethylsilyl ) Oxy ) methyl ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) -2- ( Methylsulfonyl Preparation of Pyrimidine

4- (5-(((tert-butyldimethylsilyl) oxy) methyl) -2-naphthalen-2-yl) -1H-imidazol-1-yl) -2- obtained in Preparation Example (13-2) (Methylthio) pyrimidine (12.2g, 0.0264mol) was dissolved in methylene chloride (130ml) and m-chloroperoxybenzoic acid (mCPBA, 13.7g, 0.08mol) was added at 0 ° C and stirred for 3 hours. 4- (5-(((tert-butyldimethylsilyl) oxy) methyl) -2-naphthalen-2-yl) -1H-imidazol-1-yl) -2- (methylthio) pyrimidine in TLC After disappearing completely, NaHCO ₃ was added and the organic layer was extracted with methylene chloride (CH ₂ Cl ₁₂ ), and then the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, separated and purified by column chromatography (EA: MC = 1: 5), and purified by 4- (5-(((tert-butyldimethyl). Silyl) oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) -2- (methylsulfonyl) pyrimidine was obtained.

White solid (65%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.66 (d, J = 5.6 Hz, 1H), 8.04 (s, 1H), 7.87 (dd, J = 14.7, 7.9 Hz, 3H), 7.74 (s, 1H) , 7.57 (tt, J = 6.8, 5.4 Hz, 2H), 7.44 (dd, J = 8.5, 1.6 Hz, 1H), 7.03 (d, J = 5.6 Hz, 1H), 4.83 (d, J = 1.0 Hz, 2H), 3.16 (s, 3H), 0.98 (s, 9H), 0.17 (s, 6H).

(18-2) (S)-(3-((4- (5-((( tert - Butyldimethylsilyl ) Oxy ) methyl ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) ( Cyclopropyl Methanone Production

4- (5-(((tert-butyldimethylsilyl) oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) -2- (methylsulfonyl) pyrimidine ( 5 g, 0.01 mol) was dissolved in tetrahydrofuran (50 ml), followed by (S)-(3-aminopiperidin-1 yl) (cyclopropyl) methanone hydrogen chloride (3.36 g, 0.02 mol) and triethylamine (13.9 ml, 0.1 mol) was added and stirred at 80 ° C. for 12 h. The reaction mixture was concentrated in vacuo and then separated and purified by column chromatography (EA: Hex = 1: 2) to obtain (S)-(3-((4- (5-(((tert-butyldimethylsilyl)) Oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) (cyclopropyl) methanone .

white solid (69%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.66 (d, J = 5.6 Hz, 1H), 8.04 (s, 1H), 7.87 (dd, J = 14.7, 7.9 Hz, 3H), 7.74 (s, 1H) , 7.57 (tt, J = 6.8, 5.4 Hz, 2H), 7.44 (dd, J = 8.5, 1.6 Hz, 1H), 7.03 (d, J = 5.6 Hz, 1H), 4.83 (d, J = 1.0 Hz, 2H), 3.16 (s, 3H), 0.98 (s, 9H), 0.17 (s, 6H).

(18-3) (S)- Cyclopropyl  (3-((4- (5- ( Hydroxymethyl Preparation of) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone

(S)-(3-((4- (5-(((tert-butyldimethylsilyl) oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidine -2-yl) amino) piperidin-1-yl) (cyclopropyl) methanone (4 g, 6.9 mmol) was dissolved in THF (35 ml), then 1M TBAF in THF (6.9 ml) was added and the mixture was kept at room temperature for 1 hour. Stirred The reaction mixture was concentrated in vacuo and then separated and purified by column chromatography (MC: MeOH = 20: 1) to give (S) -cyclopropyl (3-((4- (5- (hydroxymethyl) -2- (Naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone was obtained.

White solid (99%); ¹ H NMR (300 MHz, DMSO-D6) δ 8.27 (s, 1H), 8.01 (s, 1H), 7.90 (t, J = 9.3 Hz, 3H), 7.73-7.30 (m, 5H), 6.34 (d , J = 80.8 Hz, 1H), 5.08 (s, 1H), 4.49 (d, J = 5.5 Hz, 2H), 3.98 (d, J = 80.0 Hz, 2H), 3.22-2.75 (m, 2H), 1.93 1.21 (m, J = 53.2, 35.0, 26.6 Hz, 5H), 0.83-0.38 (m, J = 70.1 Hz, 5H).

(18-4) (S)-(3-((4- (5- ( Chloromethyl ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) ( Cyclopropyl ) Methanone  Produce

(S) -cyclopropyl (3-((4- (5- (hydroxymethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) a piperidin-1-yl) -methanone (3.2g, 6.8 mmol) methylene chloride (CH ₂ C _l2) after TEA (10.2 mmol, 1.42 ml) , methanesulfonyl chloride (7.5 mmol, 0.58 ml) dissolved in Put and stirred at room temperature for 12 hours. The reaction mixture was concentrated in vacuo, separated and purified by column chromatography (EA: MC = 1: 1), and purified by (S)-(3-((4- (5- (chloromethyl) -2- (naphthalene-) 2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) (cyclopropyl) methanone was obtained.

white solid (60%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.08 (s, 2H), 7.83 (dd, J = 12.5, 8.0 Hz, 3H), 7.64 (s, 1H), 7.57-7.48 (m, 2H), 7.45 ( d, J = 8.4 Hz, 1H), 6.12 (s, 1H), 5.29 (s, 1H), 4.70 (s, 2H), 3.85-3.22 (m, 4H), 1.66 (s, 5H), 0.81 (dd , J = 111.4, 63.2 Hz, 5H).

(18-5) (S)- Cyclopropyl (3-((4- (5- ( Methoxymethyl Preparation of) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone

(S)-(3-((4- (5- (chloromethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine -1-yl) (cyclopropyl) methanone (0.066 g, 0.136 mmol) was dissolved in methanol (10 ml) and stirred at 40 ° C. for 12 h. The reaction mixture was concentrated in vacuo, separated by column chromatography (EA), purified and purified by (S) -cyclopropyl (3-((4- (5- (methoxymethyl) -2- (naphthalen-2-yl). ) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone was obtained.

White solid (50%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.08 (s, 1H), 7.81 (dd, J = 12.5, 5.5 Hz, 2H), 7.65 (d, J = 42.8 Hz, 1H), 7.55-7.48 (m, 1H), 7.46 (d, J = 8.4 Hz, 1H), 6.14 (s, 1H), 4.53 (s, 1H), 3.97 (s, 1H), 3.72 (s, 1H), 3.51 (s, 2H), 3.28 (s, 1 H), 1.70 (s, 4 H), 0.81 (dd, J = 111.3, 60.5 Hz, 3H).

Example 14: Preparation of Compound 27

(19-1) 5-((( tert - Butyldimethylsilyl ) Oxy ) methyl ) -2- (2,3- Dihydrobenzofuran Preparation of -5-yl) -1H-imidazole

(2- (2,3-dihydrobenzofuran-5-yl) -1H-imidazol-5-yl) methanol (1 g, 3 mmol) obtained in (11-4) of Example 9 was replaced with N, N- After dissolving in dimethylformamide (DMF, 15ml), imidazole (0.2g, 3mmol) and tert-butyldimethylsilyl chloride (TBDMS-Cl, 0.45g, 3mmol) were added and stirred. (90%)

(19-2) 4- (5-((( tert - Butyldimethylsilyl ) Oxy ) methyl ) -2- (2,3- Dihydrobenzofuran -5-yl) -1H-imidazol-1-yl) -2- (methylthio) pyrimidine

It manufactured by the same process as the preparation example (1-5). (19%)

(19-3) (2- (2,3- Dihydrobenzofuran -5-day) -1- (2- ( Methylthio ) Pyrimidin-4-yl) -1H-imidazol-5-yl) methanol

It manufactured by the same process as (18-3) of the said Example 13.

White foam (100%); ¹ H NMR (300 MHz, CDCl ₃ ) δ 8.29 (d, J = 5.5 Hz, 1H), 7.54 (s, 1H), 7.29-7.24 (m, 1H), 7.08 (d, J = 8.2 Hz, 1H) , 6.70 (d, J = 8.3 Hz, 1H), 6.44 (d, J = 5.5 Hz, 1H), 4.61 (s, 2H), 4.56 (t, J = 8.7 Hz, 2H), 3.15 (t, J = 8.7 Hz, 2H), 2.43 (s, 3H).

(19-4) 4- (5- ( Chloromethyl ) -2- (2,3- Dihydrobenzofuran Preparation of -5-yl) -1H-imidazol-1-yl) -2- (methylthio) pyrimidine

It manufactured by the same process as (18-4) of the said Example 13. Yellow foam (53%)

(19-5) 4- (2- (2,3- Dihydrobenzofuran -5-day) -5-(( Methylthio ) methyl Preparation of) -1H-imidazol-1-yl) -2- (methylthio) pyrimidine

Sodium methanethiolate (0.3 g, 4.2 mmol) dissolved in THF and then dissolved in THF at 0 ° C. 4- (5- (chloromethyl) -2- (2,3-dihydrobenzofuran-5- Il) -1H-imidazol-1-yl) -2- (methylthio) pyrimidine (1.144 g, 3.2 mmol) was added slowly. Then stirred at room temperature for 20 hours. The reaction mixture was concentrated, poured into water, extracted with MC, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography to obtain 4- (2- (2,3-dihydrobenzofuran-5-yl) -5- ((Methylthio) methyl) -1H-imidazol-1-yl) -2- (methylthio) pyrimidine was obtained.

White foam (84%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.33 (dd, J = 5.5, 1.4 Hz, 1H), 7.58 (t, J = 0.8 Hz, 1H), 7.36-7.33 (m, 1H), 7.15-7.10 ( m, 1H), 6.75 (d, J = 8.3 Hz, 1H), 6.50 (dd, J = 5.5, 1.4 Hz, 1H), 4.62 (t, J = 8.8 Hz, 2H), 3.71 (d, J = 0.8 Hz, 2H), 3.20 (t, J = 8.8 Hz, 2H), 2.51 (d, J = 1.4 Hz, 3H), 2.19 (d, J = 1.4 Hz, 3H).

(19-6) 4- (2- (2,3- Dihydrobenzofuran -5-day) -5-(( Methylsulfonyl ) methyl Preparation of) -1H-imidazol-1-yl) -2- (methylsulfonyl) pyrimidine

It manufactured by the same process as the preparation example (1-6).

(61.3%) ¹ H NMR (300 MHz, CDCl ₃ ) δ 8.76 (d, J = 5.5 Hz, 1H), 7.96 (s, 1H), 7.31 (s, 1H), 7.11 (dd, J = 16.5, 6.8 Hz, 2H), 6.83 (d, J = 8.2 Hz, 1H), 4.67 (t, J = 8.7 Hz, 2H), 4.32 (s, 2H), 3.32 (s, 3H), 3.25 (t, J = 8.6 Hz, 2H), 3.06 (s, 3H).

(19-7) (S)- Cyclopropyl (3-((4- (2- (2,3- Dihydrobenzofuran -5-yl) -5-((methylsulfonyl) methyl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone

Prepared by the same process as in (16-5) of Example 11,

¹ H NMR (400 MHz, CD3OD) δ 8.35-8.15 (m, 1H), 7.94-7.72 (m, 1H), 7.30 (d, J = 15.7 Hz, 1H), 7.21-7.09 (m, 1H), 6.76 (t, J = 7.9 Hz, 1H), 6.46 (d, J = 76.5 Hz, 2H), 4.59 (t, J = 8.7 Hz, 2H), 4.44 (d, J = 11.5 Hz, 2H), 4.05 (dd , J = 38.2, 31.0 Hz, 2H), 3.21 (dd, J = 11.5, 6.0 Hz, 2H), 3.02 (s, 3H), 2.82 (d, J = 24.3 Hz, 1H), 1.78 (dd, J = 96.9, 61.7 Hz, 6H), 0.78 (ddd, J = 95.0, 32.8, 7.1 Hz, 5H).

Example 15: Preparation of Compound 28

(20-1) (S)- Cyclopropyl (3-((4- (5- ( ( Methylthio ) methyl Preparation of) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone

(S)-(3-((4- (5- (chloromethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) obtained in (18-4) of Example 13 above) Pyrimidin-2-yl) amino) piperidin-1-yl) (cyclopropyl) methanone (0.3 g, 0.617 mmol) was dissolved in THF followed by sodium methanethiolate (0.11 g, 1.59 mmol) And TEA (0.25ml, 1.59 mmol) were added thereto, followed by stirring at room temperature for 14 hours. The reaction mixture was concentrated in vacuo, water was added, extracted with EA, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, separated by column chromatography, purified and purified by (S) -cyclopropyl (3-((4- (5-((methylthio) methyl) ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone was obtained.

(57.9%)

(20-2) (S)- Cyclopropyl (3-((4- (5- ( ( Methylsulfonyl ) methyl Preparation of) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone

(S) -cyclopropyl (3-((4- (5-((methylthio) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) Amino) piperidin-1-yl) methanone (0.073g, 0.146mmol) was dissolved in 10ml of methanol: water = 1: 1 mixed solvent, and then OXONE (0.225g, 0.732 mmol) was added thereto and stirred at room temperature for 20 minutes. . Water was added and extracted with MC, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, separated by column chromatography, purified and purified by (S) -cyclopropyl (3-((4- (5-((methylsulfonyl)) Methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone was obtained.

(58.4%); ¹ H NMR (300 MHz, DMSO-d6) δ 8.32 (d, J = 22.0 Hz, 1H), 8.15-7.78 (m, 5H), 7.68-7.38 (m, 3H), 6.65-6.13 (m, 1H) , 4.50 (s, 2H), 4.11 (s, J = 23.4 Hz, 1H), 3.81 (s, 1H), 3.10 (s, 3H), 2.94 (s, 1H), 2.05-1.69 (m, 2H), 1.69-1.12 (m, 4H), 1.02-0.42 (m, 5H).

Example 16: Preparation of Compound 32

(S) -cyclopropyl (3-((4- (5-((methylthio) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) Amino) piperidin-1-yl) methanone (0.05g, 0.1mmol) was dissolved in acetic acid (5ml) and then sodium perborate tetrahydrate (0.015g, 0.1mmol) was added and stirred for 12 hours. The reaction mixture was concentrated in vacuo, separated by column chromatography, purified and purified by (S) -cyclopropyl (3-((4- (5-((methylsulfinyl) methyl) -2- (naphthalen-2-yl). ) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone was obtained.

(36.9%); ¹ H NMR (300 MHz, DMSO-d6) δ 8.32 (d, J = 22.0 Hz, 1H), 8.15-7.77 (m, 5H), 7.68-7.39 (m, 3H), 6.65-6.14 (m, 1H) , 4.50 (s, 2H), 4.11 (s, 1H), 3.81 (s, 1H), 3.10 (s, 3H), 2.94 (s, 1H), 2.09-1.69 (m, 2H), 1.69-1.10 (m , 4H), 0.95-0.34 (m, 5H).

Example 17: Preparation of Compound 33

(23-1) (S) -1- (4- Chloropyrimidine -2-yl) -3- (1- ( Cyclopropanecarbonyl Preparation of Piperidin-3-yl) urea

Dissolve 2-amino-4-chloropyrimidine (1 g, 7.7 mmol) in THF and add phenyl chloroformate (0.97 ml, 7.7 mmol). Triethylamine (1.6ml, 11.6mmol) was added slowly at 0 ° C. and refluxed for 3 hours. TLC confirmed that 2-amino-4-chloropyrimidine disappeared and filtered. (S)-(3-Aminopiperidin-1yl) (cyclopropyl) methanone hydrogen chloride (1.58g, 7.7mmol) and DBU (2.3ml, 15.4mmol) were added to the filtrate at 0 ° C at room temperature. Stir for 2 hours. After confirming that the phenyl (4-chloropyrimidin-2-yl) carbamate disappeared in TLC, water was added, extracted with MC, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (S) -1- (4-chloropyrimidin-2-yl) -3- (1 -(Cyclopropanecarbonyl) piperidin-3-yl) urea was obtained.

(35%) ¹ H NMR (400 MHz, DMSO-d6) δ 10.15 (d, J = 22.3 Hz, 1H), 8.95 (d, J = 29.7 Hz, 1H), 8.49 (d, J = 5.3 Hz, 1H ), 7.20 (d, J = 5.3 Hz, 1H), 3.85-3.55 (m, 4H), 3.42 (s, 1H), 3.23 (s, 1H), 1.94-1.76 (m, 2H), 1.63 (d, J = 41.7 Hz, 3H), 0.66 (s, 3H), 0.51 (d, J = 32.0 Hz, 1H).

(23-2) (S) -1- (4- (5- ( Cyanomethyl ) -2- (3,4- Dichlorophenyl Preparation of) -1H-imidazol-1-yl) pyrimidin-2-yl) -3- (1- (cyclopropanecarbonyl) piperidin-3-yl) urea

(S) -1- (4-Chloropyrimidin-2-yl) -3- (1- (cyclopropanecarbonyl) piperidin-3-yl) urea (0.1 g, 0.3 mmol) and of Example 4 2- (2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetonitrile (0.078 g, 0.3 mmol) obtained in (6-4) was purified by anhydrous DMF (1.5 ml, 0.2 M) and 0.5M KHMDS in toluene (0.17 ml, 0.33 mmol) were added slowly and stirred at 80 ° C. for 12 hours. Water was added to the reaction mixture, followed by extraction with MC. The organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (S) -1- (4- (5- (cyanomethyl) -2- (3). , 4-dichlorophenyl) -1H-imidazol-1-yl) pyrimidin-2-yl) -3- (1- (cyclopropanecarbonyl) piperidin-3-yl) urea was obtained.

(40%); ¹ H NMR (400 MHz, CD ₃ OD) δ 8.55 (d, J = 4.3 Hz, 1H), 7.85-7.71 (m, 2H), 7.68 (d, J = 11.6 Hz, 1H), 7.59 (dd, J = 8.4, 1.7 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.13 (s, 1H), 6.78 (d, J = 5.4 Hz, 1H), 3.93 (s, 2H), 2.40 (s , 1H), 2.07-1.98 (m, 3H), 1.83 (d, J = 31.6 Hz, 4H), 1.52 (d, J = 1.6 Hz, 1H), 0.77 (s, 5H).

Example 18: Preparation of Compound 34

(24-1) 4- (5-((( tert - Butyldimethylsilyl ) Oxy ) methyl ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) -2- ( Methylsulfonyl Preparation of Pyrimidine

4- (5-(((tert-butyldimethylsilyl) oxy) methyl) -2-naphthalen-2-yl) -1H-imidazol-1-yl) -2- obtained in Preparation Example (13-2) (Methylthio) pyrimidine (12.2g, 0.0264mol) was dissolved in methylene chloride (130ml) and m-chloroperoxybenzoic acid (mCPBA, 13.7g, 0.08mol) was added at 0 ° C and stirred for 3 hours. 4- (5-(((tert-butyldimethylsilyl) oxy) methyl) -2-naphthalen-2-yl) -1H-imidazol-1-yl) -2- (methylthio) pyrimidine in TLC After disappearing completely, NaHCO ₃ was added and the organic layer was extracted with methylene chloride (CH ₂ Cl ₁₂ ), and then the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, separated and purified by column chromatography (EA: MC = 1: 5), and purified by 4- (5-(((tert-butyldimethyl). Silyl) oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) -2- (methylsulfonyl) pyrimidine was obtained.

White solid (65%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.66 (d, J = 5.6 Hz, 1H), 8.04 (s, 1H), 7.87 (dd, J = 14.7, 7.9 Hz, 3H), 7.74 (s, 1H) , 7.57 (tt, J = 6.8, 5.4 Hz, 2H), 7.44 (dd, J = 8.5, 1.6 Hz, 1H), 7.03 (d, J = 5.6 Hz, 1H), 4.83 (d, J = 1.0 Hz, 2H), 3.16 (s, 3H), 0.98 (s, 9H), 0.17 (s, 6H).

(24-2) (S)-(3-((4- (5-((( tert - Butyldimethylsilyl ) Oxy ) methyl ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) ( Cyclopropyl Methanone Production

4- (5-(((tert-butyldimethylsilyl) oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) -2- (methylsulfonyl) pyrimidine ( 5 g, 0.01 mol) was dissolved in tetrahydrofuran (50 ml), followed by (S)-(3-aminopiperidin-1 yl) (cyclopropyl) methanone hydrogen chloride (3.36 g, 0.02 mol) and triethylamine (13.9 ml, 0.1 mol) was added followed by stirring at 80 ° C. for 12 h. The reaction mixture was concentrated in vacuo and then separated and purified by column chromatography (EA: Hex = 1: 2) to obtain (S)-(3-((4- (5-(((tert-butyldimethylsilyl)) Oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) (cyclopropyl) methanone .

white solid (69%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.66 (d, J = 5.6 Hz, 1H), 8.04 (s, 1H), 7.87 (dd, J = 14.7, 7.9 Hz, 3H), 7.74 (s, 1H) , 7.57 (tt, J = 6.8, 5.4 Hz, 2H), 7.44 (dd, J = 8.5, 1.6 Hz, 1H), 7.03 (d, J = 5.6 Hz, 1H), 4.83 (d, J = 1.0 Hz, 2H), 3.16 (s, 3H), 0.98 (s, 9H), 0.17 (s, 6H).

(24-3) (S)- Cyclopropyl  (3-((4- (5- ( Hydroxymethyl Preparation of) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone

(S)-(3-((4- (5-(((tert-butyldimethylsilyl) oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidine -2-yl) amino) piperidin-1-yl) (cyclopropyl) methanone (4 g, 6.9 mmol) was dissolved in THF (35 ml), then 1M TBAF in THF (6.9 ml) was added and the mixture was kept at room temperature for 1 hour. Stirred The reaction mixture was concentrated in vacuo and then separated and purified by column chromatography (MC: MeOH = 20: 1) to give (S) -cyclopropyl (3-((4- (5- (hydroxymethyl) -2- (Naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone was obtained.

White solid (99%); ¹ H NMR (300 MHz, DMSO-D6) δ 8.27 (s, 1H), 8.01 (s, 1H), 7.90 (t, J = 9.3 Hz, 3H), 7.73-7.30 (m, 5H), 6.34 (d , J = 80.8 Hz, 1H), 5.08 (s, 1H), 4.49 (d, J = 5.5 Hz, 2H), 3.98 (d, J = 80.0 Hz, 2H), 3.22-2.75 (m, 2H), 1.93 1.21 (m, J = 53.2, 35.0, 26.6 Hz, 5H), 0.83-0.38 (m, J = 70.1 Hz, 5H).

Example 19: Preparation of Compound 35

(25-1) ethyl (S) -2- (1- (2- ( Methylthio Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetate

It manufactured by the same process as the preparation example (1-5).

¹ H NMR (400 MHz, CDCl ₃ ) δ 8.29 (d, J = 5.5 Hz, 1H), 8.05 (d, J = 1.3 Hz, 1H), 7.89-7.79 (m, 3H), 7.73 (s, 1H) , 7.56-7.49 (m, 2H), 7.43 (dd, J = 8.5, 1.8 Hz, 1H), 6.49 (d, J = 5.5 Hz, 1H), 4.24 (q, J = 7.1 Hz, 2H), 3.78 ( d, J = 0.7 Hz, 2H), 2.40 (s, 3H), 1.32 (t, J = 7.2 Hz, 3H).

(25-2) ethyl (S) -2- (1- (2- ( Methylsulfonyl Preparation of Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetate

It manufactured by the same process as the preparation example (1-6).

¹ H NMR (400 MHz, CDCl ₃ ) δ 8.65 (d, J = 5.6 Hz, 1H), 8.06 (d, J = 1.4 Hz, 1H), 7.86 (ddd, J = 9.1, 8.3, 1.8 Hz, 4H) , 7.56 (tdd, J = 7.9, 6.6, 3.2 Hz, 3H), 7.44 (dd, J = 8.5, 1.8 Hz, 1H), 7.01 (d, J = 5.6 Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 3.79 (d, J = 0.9 Hz, 2H), 3.18 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H).

(25-3) ethyl (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl Preparation of)) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetate

It was prepared in the same process as in Example 16 (16-5).

¹ H NMR (400 MHz, CDCl ₃ ) δ 8.09 (s, 1H), 8.05 (s, 1H), 7.83 (dd, J = 6.6, 2.8 Hz, 2H), 7.79 (d, J = 8.6 Hz, 1H) , 7.60 (s, 1H), 7.54-7.46 (m, 2H), 7.44 (d, J = 8.5 Hz, 1H), 6.15 (s, 1H), 5.32 (s, 1H), 4.23 (q, J = 7.1 Hz, 2H), 3.93 (s, 1H), 3.77 (d, J = 0.7 Hz, 2H), 3.72 (s, 1H), 3.37 (m, 2H), 1.85-1.46 (m, 5H), 1.31 (t , J = 7.1 Hz, 3H), 0.80 (dd, J = 112.0, 56.3 Hz, 5H).

Example 20: Preparation of Compound 36

(26-1) (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl Preparation of a) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetic acid

Ethyl (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetate (0.05 g, 0.095 mmol) in conc. HCl (0.5ml) and water (0.5ml) were added thereto and stirred at room temperature for 3 hours. Extracted with methylene chloride (CH ₂ Cl ₂ ) and then the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (S) -2- (1- (2-((1- (cyclopropanecarbonyl)). Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetic acid was obtained.

White solide (25%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.07 (d, J = 16.2 Hz, 2H), 7.88-7.73 (m, 3H), 7.52 (tt, J = 7.1, 5.5 Hz, 2H), 7.43 (d, J = 8.2 Hz, 1H), 6.16 (d, J = 44.4 Hz, 2H), 4.26-4.07 (m, 1H), 3.80 (s, 2H), 3.74 (s, 1H), 3.60-2.89 (m, 3H ), 1.93-1.38 (m, 5H), 1.08-0.50 (m, 5H).

Example 21: Preparation of Compound 37

(27-1) (S) -3-((4- (5- ( Methyl cyanide ) -2- (3,4- Dichlorophenyl Preparation of) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) -N-cyclopropylpiperidine-1-carboxamide

2- (2- (3,4-dichlorophenyl) -1- (2- (piperidin-3-yl) amino) pyrimidin-4-yl) -1H-imidazol-5-yl) acetonite Reel (1g, 2.15 mmol) was dissolved in methylene chloride (CH ₂ Cl ₂ , 10ml), and then TEA (6.45 mmol, 0.9ml) was added thereto, followed by stirring at room temperature for 30 minutes. Isocyanatocyclopropane (2.15 mmol, 0.15 ml) was added thereto, followed by stirring for 15 hours. 2- (2- (3,4-dichlorophenyl) -1- (2- (piperidin-3-ylamino) pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile After disappearing from the TLC, the reaction mixture was concentrated in vacuo, separated and purified by column chromatography (MC: MeOH = 20: 1), and purified by (S) -3-((4- (5- (methyl cyanide)). -2- (3,4-Dichlorophenyl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) -N-cyclopropylpiperidine-1-carboxamide was obtained.

Yellow foam (17.4%); ¹ H NMR (400 MHz, CD ₃ OD) δ 8.33 (d, J = 5.3 Hz, 1H), 7.75 (s, 1H), 7.66 (d, J = 1.8 Hz, 1H), 7.57 (d, J = 8.3 Hz, 1H), 7.33 (ddd, J = 8.4, 2.1, 0.5 Hz, 1H), 6.61 (s, 1H), 3.91 (s, 2H), 3.86 (s, 1H), 3.69 (d, J = 12.9 Hz , 1H), 3.15-2.59 (m, 4H), 2.54 (ddd, J = 10.7, 7.2, 3.8 Hz, 1H), 1.69 (s, 2H), 1.40 (s, 3H), 0.63 (tt, J = 4.9 , 2.5 Hz, 2H), 0.46-0.35 (m, 2H). ; LRMS (ESI) m / z calcd for C 24 H 24 Cl 2 N 8 O [M + H] +: 511, Found 511.

Example 22: Preparation of Compound 38

(28-1) (S) -N- ( tert -Butyl) -3-((4- (5- ( Methyl cyanide ) -2- (3,4- Dichlorophenyl Preparation of) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxamide

Except for using Tert-butyl isocyanate (Tert-butyl isocyanate) was carried out substantially the same process as in Example 20, to give (S) -N- (tert-butyl) -3-((4- (5- (Methyl cyanide) -2- (3,4-dichlorophenyl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxamide was obtained.

(19%); ¹ H NMR (400 MHz, CD ₃ OD) δ 8.31 (d, J = 5.3 Hz, 1H), 7.74 (s, 1H), 7.64 (d, J = 1.4 Hz, 1H), 7.55 (d, J = 8.3 Hz, 1H), 7.32 (dd, J = 8.3, 2.1 Hz, 1H), 6.57 (s, 1H), 3.89 (d, J = 0.9 Hz, 2H), 3.85-3.56 (m, 3H), 3.13 (s , 1H), 2.92-2.78 (m, 2H), 2.69 (s, 1H), 1.69 (s, 2H), 1.49-1.34 (m, 2H), 1.34-1.26 (m, 9H).

Example 23: Preparation of Compound 39

(29-1) (S)- Cyclopropyl (3-((4- (5- ( Morpholinomethyl ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone

(S)-(3-((4- (5- (chloromethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) obtained in (18-4) of Example 13 above) Pyrimidin-2-yl) amino) piperidin-1-yl) (cyclopropyl) methanone (0.1g, 0.2mmol) was dissolved in THF and morpholine (0.034g, 0.4mmol) was added for 12 hours at room temperature. Stirred The reaction mixture was concentrated, water was added, extracted with EA, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography (S) -cyclopropyl (3-((4- (5- (morpholinomethyl)). -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone was obtained.

(60%) ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.06 (s, 2H), 7.91-7.74 (m, 3H), 7.65 (s, 1H), 7.56-7.47 (m, 2H), 7.45 (d , J = 8.2 Hz, 1H), 6.12 (s, 1H), 5.29 (d, J = 0.8 Hz, 1H), 4.02 (s, 1H), 3.80-3.75 (m, 3H), 3.73-3.67 (m, 1H), 3.62 (s, 2H), 3.53-3.13 (m, 3H), 2.64 (s, 4H), 2.17 (s, 1H), 1.71 (s, 5H), 1.03-0.56 (m, 5H).

Example 24: Preparation of Compound 40

(30-1) (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl ) Azepan -3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) Acetonitrile  Produce

It was prepared in the same process as in Example 16 (16-5).

¹ H NMR (400 MHz, CDCl ₃ ) δ 8.10 (s, 1H), 8.04 (d, J = 4.2 Hz, 1H), 7.88-7.79 (m, 3H), 7.71 (s, 1H), 7.57-7.48 ( m, 2H), 7.44 (d, J = 7.6 Hz, 1H), 6.54 (s, 1H), 6.14 (s, 1H), 3.82 (s, 2H), 3.20 (d, J = 65.9 Hz, 4H), 1.75 (s, 5H), 1.04 (d, J = 21.4 Hz, 3H), 0.83 (d, J = 38.4 Hz, 3H), 0.62 (s, 1H).

Example 25: Preparation of Compound 41

(31-1) (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl ) Azetidine -3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) Acetonitrile  Produce

It was prepared in the same process as in Example 16 (16-5).

¹ H NMR (400 MHz, CDCl ₃ ) δ 8.21 (s, 1H), 8.05 (s, 1H), 7.83 (d, J = 7.3 Hz, 3H), 7.61 (s, 1H), 7.52 (d, J = 3.9 Hz, 2H), 7.41 (d, J = 8.2 Hz, 1H), 6.33 (s, 1H), 5.83 (s, 1H), 4.22 (s, 2H), 3.83 (s, 4H), 1.71 (s, 1H), 1.25 (s, 1H), 0.90 (s, 2H), 0.68 (s, 2H).

Example 26: Preparation of Compound 42

(32-1) (S) -2- (1- (2-((1- ( Cyclopropylmethyl )) Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile

Except for using (chloromethyl) cyclopropane, substantially the same process as in Preparation Example (1-9) was carried out to give (S) -2- (1- (2-((1- (cyclopropylmethyl)) Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile was obtained.

¹ H NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 8.03 (s, 1H), 7.98-7.86 (m, 3H), 7.71 (s, 1H), 7.55 (s, 2H), 7.45 (s, 1H), 7.28 (s, 1H), 6.49 (s, 1H), 4.03 (s, 2H), 2.17 (s, 1H), 1.91 (s, 2H), 1.78 (s, 1H), 1.68 ( s, 1H), 1.26 (s, 2H), 0.95 (s, 2H), 0.66 (s, 1H), 0.37 (s, 2H), 0.04 (s, 1H), -0.06 (s, 1H). ; LRMS (ESI) m / z calcd for C28H29N7 [M + H] +: 464, Found 464.

Example 27: Preparation of Compound 43

(33-1) (S)- Cyclopropyl (3-((4- (5- ( ( Dimethylamino ) methyl Preparation of) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone

(S)-(3-((4- (5- (chloromethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine -1-yl) (cyclopropyl) methanone (0.3 g, 0.616 mmol) in THF (3 ml), followed by 2.0 M dimethylamine in THF (0.5 ml, 1.025 mmol) and TEA (0.14 ml, 1.025 mmol) After the addition was stirred for 12 hours at room temperature. After concentration, water was added, extraction was performed with EA, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, separated by column chromatography, purified and purified by (S) -cyclopropyl (3-((4- (5-((dimethylamino)). Methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone was obtained.

(9%); ¹ H NMR (400 MHz, CDCl ₃ ) δ 8.10 (s, 1H), 8.05 (s, 1H), 7.90-7.76 (m, 3H), 7.69 (s, 1H), 7.57-7.47 (m, 2H), 7.45 (d, J = 8.8 Hz, 1H), 6.14 (s, 1H), 5.29-5.22 (m, 1H), 3.81 (s, 1H), 3.73 (s, 2H), 3.35 (s, 3H), 2.53 (s, 5H), 1.85-1.39 (m, 5H), 1.03-0.54 (m, 5H).

Example 28: Preparation of Compound 44

(34-1) (3-((4- (5-(( tert - Butyldimethylsilyl ) Oxy ) methyl ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) ( Cyclopropyl ) Methanone  Produce

N- (3- (cyclopropanecarbonyl) phenyl) formamide (0.32g, 1.7mmol) was dissolved in THF (17ml), and 55% sodium hydride (0.133g, 3.04mmol) was added at 0 ° C for 30 minutes. Stirred Thereafter, 4- (5-(((tert-butyldimethylsilyl) oxy) methyl) -2- (naphthalen-2-yl) -1H-imidazole-1 obtained in (18-4) of Example 13 above. -Yl) -2- (methylsulfonyl) pyrimidine (1g, 2.02mmol) was added thereto, followed by stirring at 60 ° C for 12 hours. The reaction mixture was concentrated, separated by column chromatography (EA: HX = 1: 3), purified and purified by (3-((4- (5-((tert-butyldimethylsilyl) oxy) methyl) -2- ( Naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) (cyclopropyl) methanone was obtained.

(56%); ¹ H NMR (400 MHz, DMSO-d6) δ 10.07 (s, 1H), 8.54 (d, J = 5.3 Hz, 1H), 8.16 (s, 2H), 8.00 (dd, J = 6.0, 3.3 Hz, 1H ), 7.91 (d, J = 8.1 Hz, 2H), 7.81 (s, 1H), 7.59-7.41 (m, 4H), 6.96 (s, 1H), 6.71 (d, J = 5.1 Hz, 1H), 4.06 (s, 2H), 2.73 (dd, J = 11.9, 6.0 Hz, 1H), 1.09-0.96 (m, 4H).

(34-2) (3-((4- (5- ( Hydroxymethyl Preparation of) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) (cyclopropyl) methanone

It manufactured by the same process as (18-3) of the said Example 13. (100%)

(34-3) (3-((4- (5- ( Chloromethyl ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) (cyclopropyl)

It manufactured by the same process as (18-5) of the said Example 13. (58%)

(34-4) 2- (1- (2-((3- ( Cyclopropanecarbonyl Preparation of (phenyl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile

(3-((4- (5- (chloromethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidine-2 obtained in (34-4) of Example 28 above) -Yl) amino) phenyl) (cyclopropyl) (0.1g, 0.21mmol) was dissolved in DMSO (3ml) and NaCN (0.02g, 0.42mmol) was added thereto and stirred at room temperature for 12 hours. The reaction mixture was concentrated, water was added, extracted with EA, and the organic layer was washed with water and brine. Thereafter, water was removed with anhydrous magnesium sulfate (MgSO ₄ ), the solvent was evaporated, and then separated and purified by column chromatography to give 2- (1- (2-((3- (cyclopropanecarbonyl) phenyl) amino) Pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile was obtained.

(67%) ¹ H NMR (400 MHz, DMSO-d6) δ 10.07 (s, 1H), 8.54 (d, J = 5.3 Hz, 1H), 8.16 (s, 2H), 8.00 (dd, J = 6.0, 3.3 Hz, 1H), 7.91 (d, J = 8.1 Hz, 2H), 7.81 (s, 1H), 7.59-7.41 (m, 4H), 6.96 (s, 1H), 6.71 (d, J = 5.1 Hz, 1H), 4.06 (s, 2H), 2.73 (dd, J = 11.9, 6.0 Hz, 1H), 1.09-0.96 (m, 4H).

Example 29: Preparation of Compound 45

(35-1) Cyclopropyl (3-((4- (5- ( Methoxymethyl ) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) phenyl) methanone

It manufactured by the same process as (18-5) of the said Example 13.

(31%) ¹ H NMR (400 MHz, DMSO-d6) δ 10.05 (s, 1H), 8.53 (d, J = 5.3 Hz, 1H), 8.20 (s, 1H), 8.15 (s, 1H), 8.02 7.95 (m, 1H), 7.90 (d, J = 8.8 Hz, 2H), 7.81 (s, 1H), 7.52 (ddd, J = 18.5, 8.1, 2.5 Hz, 4H), 7.42 (s, 1H), 6.94 (s, 1H), 6.70 (d, J = 5.3 Hz, 1H), 4.42 (s, 2H), 3.36 (s, 3H), 2.75 (ddd, J = 12.5, 7.0, 5.4 Hz, 1H), 1.08 0.98 (m, 4 H).

Example 30: Preparation of Compound 46

(36-1) (S) -2- (2- (3,4- Dichlorophenyl ) -1- (2-((1- Fibaroylpiperidine -3-yl) amino) pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile

Cyclopropane carbonylchloride and 2- (2- (naphthalen-2-yl) -1- (2- (piperidin-3-ylamino) pyrimidin-4-yl) -1H-imidazol-5-yl Tert-butyl (S) -3- (4- (5- (cyanomethyl) -2- (3,4) obtained in (6-7) of Example 4 with fibaroyl chloride instead of acetonitrile -Preparative Examples (1-7) to (1) except that -dichlorophenyl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) piperidine-1-carboxylate was used Substantially the same process as -9), to give (S) -2- (2- (3,4-dichlorophenyl) -1- (2-((1-fibaroylpiperidin-3-yl) Amino) pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile.

Pink foam (13%); ¹ H NMR (400 MHz, CD ₃ OD) δ 8.34 (d, J = 5.2 Hz, 1H), 7.72 (s, 1H), 7.63 (s, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.33 (dd, J = 8.4, 2.0 Hz, 1H), 6.58 (s, 1H), 4.21 (s, 2H), 3.90 (s, 2H), 2.97-2.84 (m, 1H), 2.80 (s, 1H) , 1.79 (s, 2H), 1.52 (s, 2H), 1.28 (s, 2H), 1.27-1.12 (m, 9H). ; LRMS (ESI) m / z calcd for C 25 H 27 Cl 2 N 7 O [M + H] +: 512, Found 512.

Example 31: Preparation of Compound 47

(37-1) tert -Butyl (S) -3-((4- (5- ( Methyl cyanide Preparation of) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) pyrrolidine-1-carboxylate

It manufactured by the same process as the said manufacture example (1-7).

¹ H NMR (400 MHz, CDCl ₃ ) δ 8.11 (s, 1H), 8.04 (s, 1H), 7.86-7.81 (m, 3H), 7.66 (s, 1H), 7.56-7.49 (m, 2H), 7.44 (dd, J = 8.5, 1.6 Hz, 1H), 6.17 (s, 1H), 5.58 (s, 1H), 3.82 (d, J = 0.6 Hz, 2H), 3.73-3.00 (m, 5H), 1.98 1.61 (m, 2 H), 1.45 (s, 9 H).

(37-2) (S) -2- (2- (naphthalen-2-yl) -1- (2- ( Pyrrolidine -3-yl) amino) pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile

It manufactured by the same process as the said Preparation Example (1-8).

(37-3) (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl ) Pyrrolidine Preparation of -3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile

It manufactured by the same process as Preparation Example (1-9).

¹ H NMR (400 MHz, CD ₃ OD) δ 8.33-8.25 (m, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.91 (dt, J = 8.8, 4.6 Hz, 3H), 7.79 (d , J = 6.1 Hz, 1H), 7.59-7.53 (m, 2H), 7.49-7.42 (m, 1H), 6.69 (s, 1H), 3.95 (s, 2H), 3.77 (d, J = 4.1 Hz, 1H), 3.68-3.41 (m, 2H), 3.02 (s, 2H), 2.04 (d, J = 9.6 Hz, 1H), 1.69-1.54 (m, 3H), 1.49-1.46 (m, 1H), 0.87 0.81 (m, 3 H).

Example 32: Preparation of Compound 48

(38-1) (S) -2- (1- (2-((1- ( Cyclobutanecarbonyl )) Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile

Except for using cyclobutane carbonyl chloride, substantially the same process as in Preparation Example (1-9) was carried out to give (S) -2- (1- (2-((1- (cyclobutanecarbonyl)) Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile was obtained.

¹ H NMR (400 MHz, CD ₃ OD) δ 8.43 (d, J = 20.9 Hz, 1H), 8.22 (s, 1H), 8.13 (d, J = 20.4 Hz, 1H), 7.98 (dd, J = 12.6 , 6.7 Hz, 3H), 7.73-7.61 (m, 2H), 7.55-7.47 (m, 1H), 6.85 (d, J = 32.3 Hz, 1H), 4.20 (s, 1H), 4.19-4.16 (m, 1H), 3.87 (s, 1H), 2.89-2.41 (m, 3H), 2.38-2.12 (m, 3H), 2.02 (dd, J = 17.8, 9.0 Hz, 2H), 1.82 (d, J = 30.7 Hz , 2H), 1.52-1.20 (m, 5H), 0.65 (s, 1H). ; LRMS (ESI) m / z calcd for C 29 H 29 N 7 O [M + H] +: 492, Found 492.

Example 33: Preparation of Compound 49

(39-1) (S) -2- (1- (2-((1- ( Cyclohexanecarbonyl ) Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) Acetonitrile  Produce

Except for using cyclohexanecarbonyl chloride, substantially the same process as in Preparation Example (1-9) was carried out to give (S) -2- (1- (2-((1- (cyclohexanecarbonyl)) Piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazol-5-yl) acetonitrile was obtained.

¹ H NMR (400 MHz, DMSO-d6) δ 8.32 (d, J = 19.2 Hz, 1H), 8.00 (s, 1H), 7.91 (d, J = 21.9 Hz, 3H), 7.73 (d, J = 37.4 Hz, 1H), 7.56 (s, 2H), 7.40 (s, 1H), 6.54 (s, 1H), 4.01 (s, 2H), 3.88 (s, 1H), 3.56 (s, 1H), 2.76 (d , J = 69.1 Hz, 3H), 2.21 (s, 1H), 1.90 (s, 1H), 1.62 (s, 4H), 1.27 (d, J = 29.4 Hz, 7H), 0.85 (s, 2H), 0.60 (s, 1 H). ; LRMS (ESI) m / z calcd for C 31 H 33 N 7 O [M + H] +: 520, Found 520.

Example 34: Preparation of Compound 50

(40-1) 2- (2- (3,4- Dichlorophenyl ) -1- (2- ( Methylthio Preparation of Pyridin-4-yl) -1H-imidazol-5-yl) acetonitrile

Except for using 4-chloro-2- (methylthio) pyridine instead of 4-chloro-2- (methylthio) pyrimidine, substantially the same process as in (6-5) of Example 4 was carried out. (2- (3,4-Dichlorophenyl) -1- (2- (methylthio) pyridin-4-yl) -1H-imidazol-5-yl) acetonitrile was obtained.

(40-2) 2- (2- (3,4- Dichlorophenyl ) -1- (2- ( Methylsulfonyl ) Pyridin-4-yl) -1H-imidazol-5-yl) acetonitrile

2- (2 instead of 2- (2- (3,4-dichlorophenyl) -1- (2- (methylthio) pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile Example 6 except for using-(3,4-dichlorophenyl) -1- (2- (methylthio) pyridin-4-yl) -1H-imidazol-5-yl) acetonitrile Substantially the same process as -6), to thereby carry 2- (2- (3,4-dichlorophenyl) -1- (2- (methylsulfonyl) pyridin-4-yl) -1H-imidazole-5 -Yl) acetonitrile was obtained.

(40-3) (S) -2- (1- (2-((1- ( Cyclopropanecarbonyl )) Piperidin-3-yl) amino) pyridin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetonitrile

2- (2- (3,4-dichlorophenyl) -1- (2- (methylsulfonyl) pyrimidin-4-yl) -1H-imidazol-5-yl) 2- (instead of acetonitrile Example 4 except 2- (3,4-dichlorophenyl) -1- (2- (methylsulfonyl) pyridin-4-yl) -1H-imidazol-5-yl) acetonitrile (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) by substantially the same process as in (6-7) to (6-9) of ) Amino) pyridin-4-yl) -2- (3,4-dichlorophenyl) -1H-imidazol-5-yl) acetonitrile.

¹ H NMR (400 MHz, CD ₃ OD) δ 8.06 (dd, J = 15.0, 5.3 Hz, 1H), 7.66 (s, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.29 (t, J = 6.9 Hz, 1H), 6.44 (dd, J = 19.4, 10.8 Hz, 2H), 4.30 (d, J = 11.8 Hz, 1H), 4.16-4.02 (m , 1H), 3.92 (t, J = 4.7 Hz, 3H), 3.81-3.71 (m, 1H), 3.55 (dd, J = 13.2, 7.3 Hz, 1H), 3.38 (d, J = 11.3 Hz, 1H) , 2.95-2.85 (m, 1H), 2.11-1.47 (m, 6H), 0.89-0.68 (m, 3H), 0.56 (dd, J = 13.5, 6.6 Hz, 1H).

Characterization JNK3  Enzyme activity

Changes in JNK3 enzyme activity by treatment of imidazole derivatives according to the present invention were confirmed via IC ₅₀ .

First, the substrate was prepared in the prepared base reaction buffer solution (20 mM Hepes, pH 7.5), 10 mM MgCl ₂ , 1 mM EGTA, 0.02% Brij35, 0.02 mg / ml BSA, 0.1 mM Na ₃ VO ₄ , 2 mM DTT, 1% DMSO). After the addition, human JNK3 enzyme in the prepared substrate solution was added and mixed. Substrate ATP (10 μM) and ATF2 (3 μM) were used, of which ATP was used as a common substrate. Next, the compounds prepared according to the above examples dissolved in 100% DMSO were put in the enzyme reaction solution, respectively, and incubated at room temperature for 20 minutes. Thereafter, ³³ P-ATP was added to the reaction mixture to initiate the reaction, and then incubated at room temperature for 2 hours, and enzyme activity was detected by a filter-binding method.

Specifically, 25 μl of P81 was slowly spotted and placed in a scintillation vial and washed four times for 10 minutes with 0.75% phosphoric acid and once for 5 minutes with acetone. 5 ml of a scintillation cocktail was placed in the scintillation container and the signal was read by a scintillation counter. IC ₅₀ values of each compound for JNK3 enzyme activity are shown in Tables 1 and 2 below.

compound IC ₅₀ compound IC ₅₀ 17a +++ 35 +++ 17b +++ 36 +++ 18a +++ 37 +++ 18b +++ 38 +++ 18d +++ 39 +++ 18h +++ 40 +++ 20e +++ 41 ++ 23a +++ 42 ++ 23b +++ 43 +++ 23c +++ 44 +++ 24 +++ 45 +++ 25 +++ 46 +++ 32 +++ 47 ++ 33 + 48 +++ 34 ++ 49 +++ 50 +++

compound IC ₅₀ (nM) JNK1 JNK2 JNK3 JNK3 20c 98 51 5 +++ 27 326 92 11 +++ 28 798 207 9 +++ 33 > 10000 > 10000 > 10000 + 37 513 56 3 +++ 38 316 60 8 +++ 40 962 241 24 +++ 41 > 10000 1020 85 ++ 42 984 354 30 ++ 44 359 268 6 +++ 46 448 81 8 +++ 47 > 10000 1347 99 ++ 48 171 102 7 +++ 49 354 154 15 +++

In Table 1 and Table 2, "+" represents a case where the IC ₅₀ value is> 100 nM, "++" represents a case where the IC ₅₀ value is 30 nM to 100 nM, and "+++" represents the IC. _The case where the value of ₅₀ is <30 nM is shown.

Referring to Table 1 and Table 2, the imidazole derivatives according to the present invention was found to have excellent inhibitory activity against JNK3.

Although the above has been described with reference to a preferred embodiment of the present invention, those skilled in the art will be able to variously modify and change the present invention without departing from the spirit and scope of the invention as set forth in the claims below. It will be appreciated.

Claims (8)

Novel imidazole derivatives having JNK inhibitory activity represented by Formula 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof;
<Formula 1>

In Formula 1, Q represents N or CH;
R ₁ represents a C ₅ -C ₁₆ aryl group, a C ₄ -C ₁₀ heteroaryl group, a C ₃ -C ₁₀ cycloalkyl group or a C ₁ -C ₁₀ heterocycloalkyl group;
R ₂ is a hydrogen atom, a C ₁ -C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, C ₁ -C ₆ Alkoxy C ₁ -C ₆ alkyl group, -C (R _a R _b ) CN wherein R _a and R _b each independently represent a hydrogen atom, a C ₁ -C ₆ alkyl group or a halogen atom, a carboxyl group, a carboxylic acid C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, aminocarbonyl (-C (= 0 )-) Group, aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₂ -C ₁₂ dialkyl aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, amino C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino C ₁ -C ₆ alkyl group, C _1- C ₆ alkyl sulfinyl (-S (= O)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl sulfonyl (-S (= O) _2- ) C ₁ -C ₆ alkyl group, C ₃ -C ₁₀ cycloalkyl group, C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, C ₁ -C ₁₀ heterocycloalkyl C ₁ -C ₆ alkyl group, C ₅ -C ₈ aryl C ₁ -C ₆ alkyl group or C ₂ -C ₈ heteroaryl C ₁ -C ₆ alkyl group;
L is a single bond, a C ₅ -C ₁₀ arylene group, a C ₃ -C ₁₀ cycloalkylene group, a C ₂ -C ₈ heterocycloalkylene group or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C (= 0)-) group,
R ₃ represents a hydrogen atom, C ₁ -C ₆ alkyl group, hydroxy C ₁ -C ₆ alkyl group, C ₃ -C ₁₀ cycloalkyl group, C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, C ₁ -C ₁₀ hetero Cycloalkyl group, C ₁ -C ₁₀ heterocycloalkyl C ₁ -C ₆ alkyl group, C ₅ -C ₁₀ aryl group, C ₅ -C ₁₀ aryl C ₁ -C ₆ alkyl group, C ₅ -C ₁₀ heteroaryl group, C ₅ -C ₁₀ heteroaryl C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) group, C ₃ -C ₁₀ cycloalkyl carbonyl (-C (= 0)-) group, C ₃ -C ₈ heterocycloalkyl carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) group, C ₃ -C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group, C ₂ -C ₈ heterocycloalkyl amino carbonyl (-C (= 0) Group, C ₅ -C ₁₀ arylamino carbonyl (-C (= 0)-) group, C ₅ -C ₁₀ heteroaryl amino carbonyl (-C (= 0)-) group, C ₁ -C ₆ Alkyl sulfonyl (-S (= O) _2- ) groups, C ₃ -C ₈ cycloalkyl sulfonyl (-S (= O) _2- ) groups, C ₃ -C ₈ heterocycloalkyl sulfonyl (-S (= O) _2- ) group, C ₅ -C ₁₀ aryl sulfonyl (-S (= O) _2- ) group or C ₅ -C ₁₀ heteroaryl sulfonyl Represents a (-S (= 0) _2- ) group;
At least one or more of the hydrogen atoms included in R ₁ , R ₂ , L and R ₃ of Formula 1 may each independently be a halogen atom (F, Cl, Br, I), a C ₁ -C ₆ haloalkyl group, C _1- It may be unsubstituted or substituted with any one of a C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxyl group and an amino group. There is;
When R ₂ is —CH ₂ CN, L is a single bond, a C ₅ -C ₁₀ arylene group, a C ₂ -C ₈ heterocycloalkylene group or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C ( = 0)-) group, where
When L is a single bond, except when R ₃ is a C ₁ -C ₆ alkyl group,
When L is a C ₄ -C ₅ heterocycloalkylene group R ₃ is a C ₃ -C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl amino carbonyl (-C ( = 0)-) group or C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group.
The method of claim 1,
In Formula 1, Q represents N or CH;
R ₁ represents a C ₅ -C ₁₆ aryl group, a C ₄ -C ₁₀ heteroaryl group, a C ₃ -C ₁₀ cycloalkyl group or a C ₁ -C ₁₀ heterocycloalkyl group;
R ₂ is a hydrogen atom, a C ₁ -C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, C ₁ -C ₆ Alkoxy C ₁ -C ₆ alkyl group, -C (R _a R _b ) CN wherein R _a and R _b each independently represent a hydrogen atom, a C ₁ -C ₆ alkyl group or a halogen atom, a carboxyl group, a carboxylic acid C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, aminocarbonyl (-C (= 0 )-) Group, aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₂ -C ₁₂ dialkyl aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, amino C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino C ₁ -C ₆ alkyl group, C _1- C ₆ alkyl sulfinyl (-S (= O)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl sulfonyl (-S (= O) _2- ) C ₁ -C ₆ alkyl group, C ₃ -C ₁₀ cycloalkyl group, C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, C ₁ -C ₁₀ heterocycloalkyl C ₁ -C ₆ alkyl group, C ₅ -C ₈ aryl C ₁ -C ₆ alkyl group or C ₂ -C ₈ heteroaryl C ₁ -C ₆ alkyl group;
L represents a single bond, a C ₃ -C ₁₀ cycloalkylene group, a C ₂ -C ₈ heterocycloalkylene group, or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C (= 0)-) group;
R ₃ is a hydrogen atom, a C ₁ -C ₆ alkyl group, a C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, a C ₃ -C ₁₀ cycloalkyl carbonyl (-C (= 0)-) group, C _3- A C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group or a C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) group;
At least one or more of the hydrogen atoms included in R ₁ , R ₂ , L and R ₃ of Formula 1 may each independently be a halogen atom (F, Cl, Br, I), a C ₁ -C ₆ haloalkyl group, C _1- May be unsubstituted or substituted with any one of a C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxy group and an amino group;
When R ₂ is —CH ₂ CN, L is a single bond, a C ₅ -C ₁₀ arylene group, a C ₂ -C ₈ heterocycloalkylene group or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C ( = 0)-) group, where
When L is a single bond, except when R ₃ is a C ₁ -C ₆ alkyl group,
When L is a C ₄ -C ₅ heterocycloalkylene group R ₃ is a C ₃ -C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl amino carbonyl (-C ( = 0)-) group or C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group,
Novel imidazole derivatives having JNK inhibitory activity, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof.
The method of claim 1,
In Formula 1, Q represents N or CH;
R ₁ represents a C ₅ -C ₁₆ aryl group or a C ₄ -C ₁₀ heteroaryl group;
R ₂ is a C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy C ₁ -C ₆ alkyl group, -C (R _a R _b ) CN (wherein R _a and R _b are each independently a hydrogen atom, C _1- C ₆ alkyl group or halogen atom), C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)- ) C ₁ -C ₆ alkyl group, aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) C ₁ -C ₆ Alkyl group, C ₁ -C ₆ alkyl amino C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl sulfinyl (-S (= O)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl sulfonyl S (= 0) _2- ) C ₁ -C ₆ alkyl group, C ₁ -C ₁₀ heterocycloalkyl C ₁ -C ₆ alkyl group, or C ₂ -C ₈ heteroaryl C ₁ -C ₆ alkyl group;
L represents a single bond, a C ₃ -C ₁₀ cycloalkylene group, a C ₂ -C ₈ heterocycloalkylene group, or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C (= 0)-) group;
R ₃ is a hydrogen atom, a C ₁ -C ₆ alkyl group, a C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, a C ₃ -C ₁₀ cycloalkyl carbonyl (-C (= 0)-) group, C _3- A C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group or a C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) group;
At least one or more of the hydrogen atoms included in R ₁ , R ₂ , L and R ₃ of Formula 1 may each independently be a halogen atom (F, Cl, Br, I), a C ₁ -C ₆ haloalkyl group, C _1- May be unsubstituted or substituted with any one of a C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxy group and an amino group;
When R ₂ is —CH ₂ CN, L is a single bond, a C ₅ -C ₁₀ arylene group, a C ₂ -C ₈ heterocycloalkylene group or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C ( = 0)-) group, where
When L is a single bond, except when R ₃ is a C ₁ -C ₆ alkyl group,
When L is a C ₄ -C ₅ heterocycloalkylene group R ₃ is a C ₃ -C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl amino carbonyl (-C ( = 0)-) group or C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group,
Novel imidazole derivatives having JNK inhibitory activity, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof.
The method of claim 1,
In Formula 1, Q represents N or CH;
R ₁ represents a C ₅ -C ₁₆ aryl group, a C ₄ -C ₁₀ heteroaryl group, a C ₃ -C ₁₀ cycloalkyl group or a C ₁ -C ₁₀ heterocycloalkyl group;
R ₂ is a C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy C ₁ -C ₆ alkyl group, -C (R _a R _b ) CN (wherein R _a and R _b are each independently a hydrogen atom, C _1- A C ₆ alkyl group or a halogen atom, at least one of R _a and R _b represents a C ₁ -C ₆ alkyl group or represents a halogen atom), C ₁ -C ₆ alkyl carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkoxy carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, aminocarbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl amino C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl sulfinyl (-S (= O)-) C ₁ -C ₆ alkyl group, C ₁ -C ₆ alkyl sulfonyl (-S (= O) _2- ) C ₁ -C ₆ alkyl group, C ₁ -C ₁₀ heterocycloalkyl C ₁ -C _{A 6} alkyl group, or a C ₂ -C ₈ heteroaryl C ₁ -C ₆ alkyl group;
L represents a single bond, a C ₃ -C ₁₀ cycloalkylene group, a C ₂ -C ₈ heterocycloalkylene group, or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C (= 0)-) group;
R ₃ is a hydrogen atom, a C ₁ -C ₆ alkyl group, a C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, a C ₃ -C ₁₀ cycloalkyl carbonyl (-C (= 0)-) group, C _3- A C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group or a C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) group;
At least one or more of the hydrogen atoms included in R ₁ , R ₂ , L and R ₃ of Formula 1 may each independently be a halogen atom (F, Cl, Br, I), a C ₁ -C ₆ haloalkyl group, C _1- Which may be unsubstituted or substituted with any one of a C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxyl group and an amino group,
Novel imidazole derivatives having JNK inhibitory activity, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof.
The method of claim 1,
In Formula 1, Q represents N or CH,
R ₁ represents a C ₅ -C ₁₆ aryl group, a C ₄ -C ₁₀ heteroaryl group or a C ₄ -C ₁₀ heterocycloalkyl group;
R ₂ is —CH ₂ CN;
L is a single bond, a C ₅ -C ₁₀ arylene group, a C ₂ -C ₈ heterocycloalkylene group or a C ₂ -C ₈ heterocycloalkylene-aminocarbonyl (-C (= 0)-) group,
R ₃ is a hydrogen atom, a C ₁ -C ₆ alkyl group, a C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group, a C ₃ -C ₁₀ cycloalkyl carbonyl (-C (= 0)-) group, C _3- A C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group or a C ₁ -C ₆ alkyl amino carbonyl (-C (= 0)-) group;
Herein, when L is a single bond, except that R ₃ is a C ₁ -C ₆ alkyl group,
When L is a C ₄ -C ₅ heterocycloalkylene group R ₃ is a C ₃ -C ₈ cycloalkyl amino carbonyl (-C (= 0)-) group, C ₁ -C ₆ alkyl amino carbonyl (-C ( = 0)-) group or C ₃ -C ₁₀ cycloalkyl C ₁ -C ₆ alkyl group;
At least one or more of the hydrogen atoms included in R ₁ , R ₂ , L and R ₃ of Formula 1 may each independently be a halogen atom (F, Cl, Br, I), a C ₁ -C ₆ haloalkyl group, C _1- Which may be unsubstituted or substituted with any one of a C ₆ alkyl group, a C ₂ -C ₆ alkenyl group, a C ₂ -C ₆ alkynyl group, a C ₁ -C ₆ alkoxy group, a hydroxyl group and an amino group,
Novel imidazole derivatives having JNK inhibitory activity, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof.
Novel imidazole derivatives having JNK inhibitory activity, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof, which compounds are selected from the group consisting of the following compounds;
(1) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalene-2- Yl) -1H-imidazol-5-yl) propanenitrile
(2) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalene-2- Yl) -1H-imidazol-5-yl) -2-methylpropanenitrile
(3) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalene-2- Yl) -1H-imidazol-5-yl) acetamide
(4) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4- Dichlorophenyl) -1H-imidazol-5-yl) acetamide
(5) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalene-2- Yl) -1H-imidazol-5-yl) -N, N-dimethylacetamide
(6) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalene-2- Yl) -1H-imidazol-5-yl) -2-methylpropanamide
(7) (S) -cyclopropyl (3-((4- (5-ethyl-2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) pi Ferridin-1-yl) methanone
(8) (S) -cyclopropyl (3-((4- (5- (methoxymethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl ) Amino) piperidin-1-yl) methanone
(9) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4- Dichlorophenyl) -1H-imidazol-5-yl) acetic acid
(10) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4- Dichlorophenyl) -1H-imidazol-5-yl)
(11) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4- Dichlorophenyl) -1H-imidazol-5-yl) -2-fluoroacetamide
(12) (S) -2- (1- (2- (1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (2,3-di Hydrobenzofuran-5-yl) -1H-imidazol-5-yl) acetonitrile
(13) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (3,4- Dichlorophenyl) -1H-imidazol-5-yl) propanenitrile
(14) (S) -cyclopropyl (3-((4- (2- (2,3-dihydrobenzofuran-5-yl) -5-((methylsulfonyl) methyl) -1H-imidazole- 1-yl) pyrimidin-2-yl) amino) piperidin-1-yl) methanone
(15) (S) -cyclopropyl (3-((4- (5-((methylsulfonyl) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidine- 2-yl) amino) piperidin-1-yl) methanone
(16) (S) -cyclopropyl (3-((4- (5- (methylsulfinyl) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidine-2 -Yl) amino) piperidin-1-yl) methanone
(17) (S) -1- (4- (5- (cyanomethyl) -2- (3,4-dichlorophenyl) -1H-imidazol-1-yl) pyrimidin-2-yl)- 3- (1- (cyclopropanecarbonyl) piperidin-3-yl) urea
(18) (S) -cyclopropyl (3-((4- (5- (hydroxymethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl ) Amino) piperidin-1-yl) methanone
(19) (S) -ethyl 2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalene-2 -Yl) -1H-imidazol-5-yl) acetate
(20) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalene-2- Yl) -1H-imidazol-5-yl) acetic acid
(21) (S) -3-((4- (5- (cyanomethyl) -2- (3,4-dichlorophenyl) -1H-imidazol-1-yl) pyrimidin-2-yl) Amino) -N-cyclopropylpiperidine-1-carboxamide
(22) (S) -N- (tert-butyl) -3-((4- (5- (cyanomethyl) -2- (3,4-dichlorophenyl) -1H-imidazol-1-yl ) Pyrimidin-2-yl) amino) piperidine-1-carboxamide
(23) (S) -cyclopropyl (3-((4- (5- (morpholinomethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl ) Amino) piperidin-1-yl) methanone
(24) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) azpan-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl ) -1H-imidazol-5-yl) acetonitrile
(25) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) azetidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl ) -1H-imidazol-5-yl) acetonitrile
(26) (S) -2- (1- (2-((1- (cyclopropylmethyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl ) -1H-imidazol-5-yl) acetonitrile
(27) (S) -cyclopropyl (3-((4- (5-((dimethylamino) methyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidine- 2-yl) amino) piperidin-1-yl) methanone
(28) 2- (1- (2-((3- (cyclopropanecarbonyl) phenyl) amino) pyrimidin-4-yl) -2- (naphthalen-2-yl) -1H-imidazole-5- A) acetonitrile
(29) cyclopropyl (3-((4- (5- (methoxymethyl) -2- (naphthalen-2-yl) -1H-imidazol-1-yl) pyrimidin-2-yl) amino) phenyl Methanone
(30) (S) -2- (2- (3,4-dichlorophenyl) -1- (2-((1-pivaloylpiperidin-3-yl) amino) pyrimidin-4-yl) -1H-imidazol-5-yl) acetonitrile
(31) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) pyrrolidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalene-2- Yl) -1H-imidazol-5-yl) acetonitrile
(32) (S) -2- (1- (2-((1- (cyclobutanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalene-2- Yl) -1H-imidazol-5-yl) acetonitrile
(33) (S) -2- (1- (2-((1- (cyclohexanecarbonyl) piperidin-3-yl) amino) pyrimidin-4-yl) -2- (naphthalene-2- Yl) -1H-imidazol-5-yl) acetonitrile
(34) (S) -2- (1- (2-((1- (cyclopropanecarbonyl) piperidin-3-yl) amino) pyridin-4-yl) -2- (3,4-di Chlorophenyl) -1H-imidazol-5-yl) acetonitrile.
An imidazole derivative represented by Formula 1 according to any one of claims 1 to 6, a pharmaceutically acceptable salt thereof, optical isomer thereof, hydrate or solvate thereof as an active ingredient,
Pharmaceutical composition for the prevention or treatment of degenerative neurological diseases.
The method of claim 7, wherein
The degenerative neurological disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis or stroke degenerative neurological disease prevention or treatment pharmaceutical composition.